ANI Pharmaceuticals, Inc
(NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The co...

Website: http://www.anipharmaceuticals.com

Founded: 2001

Full Time Employees: 338

Sector: Healthcare

Industry: Drug Manufacturers-Specialty & Generic

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-08-29	2005-06-30	2000-09-30

net revenues	237,462,000	247,060,000	227,813,000	211,371,000	197,122,000	190,574,000	148,332,000	138,040,000	137,430,000	131,654,000	131,829,000	116,547,000	106,786,000	94,232,000	83,821,000	73,855,000	64,477,000	60,929,000	52,061,000	48,625,000	54,521,000	57,252,000	52,979,000	48,470,000	49,774,000	47,966,000	51,337,000	54,357,000	52,887,000	57,122,000	50,703,000	47,268,000	46,483,000	47,286,000	48,164,000	44,764,000	36,628,000	38,205,000	38,525,000	31,337,000	20,555,000	18,035,000	19,972,000	19,516,000	18,799,000	21,037,000	17,387,000	6,647,000	10,899,000	10,532,330	7,836,222	6,151,539
operating expenses
cost of sales	93,582,000	100,269,000	93,389,000	74,615,000	73,037,000	80,280,000	63,075,000	57,698,000	49,157,000	53,420,000	48,101,000	42,284,000	37,708,000	36,326,000	32,894,000	35,294,000	34,271,000	33,898,000	24,413,000	22,314,000	19,985,000	15,654,250	20,118,000	20,695,000	21,804,000	11,339,750	15,002,000	15,632,000	14,725,000	13,222,750	15,605,000	16,593,000	20,693,000	14,646,500	21,078,000	21,122,000	16,386,000	16,906,000	16,669,000	11,795,000	3,410,000	3,540,000	3,260,000	3,141,000	2,751,000	3,673,000	3,061,000	2,117,000	2,622,000	2,907,805	2,629,119	2,098,540
research and development	10,600,000	12,261,000	12,304,000	16,535,000	10,564,000	16,646,000	10,128,000	7,296,000	10,511,000	9,867,000	11,121,000	7,374,000	5,924,000	5,222,000	7,657,000	4,165,000	5,274,000	3,140,000	2,456,000	2,805,000	2,968,000	3,079,500	2,939,000	3,035,000	6,344,000	3,782,000	4,982,000	5,773,000	4,373,000	2,976,500	4,667,000	5,137,000	2,102,000	1,604,750	2,634,000	2,167,000	1,618,000	135,000	1,041,000	764,000	966,000	661,000	815,000	995,000	403,000	568,000	883,000	851,000	376,000	524,539	453,897	437,184	972,049	2,434,742	3,872,736	5,398,305	5,183,217	6,701,127	11,500,053	11,116,323	14,864,420	11,905,433	9,716,091	8,657,606	9,426,870	3,743,967	3,371,217	3,493,576	3,072,240	3,855,464	5,322,472	3,934,118	2,677,946	1,211,919	1,145,764	1,347,361	913,852	955,943	766,592	1,114,588	1,018,877	1,015,228	1,314,283		1,927,890
selling, general, and administrative	73,655,000	82,790,000	76,656,000	81,771,000	76,528,000	69,719,000	79,075,000	52,821,000	48,021,000	44,462,000	42,007,000	38,760,000	36,468,000	33,188,000	30,081,000	31,958,000	28,817,000	30,706,000	17,181,000	18,820,000	17,587,000	12,655,250	15,725,000	21,213,000	13,683,000	10,457,250	14,357,000	14,188,000	13,284,000	7,671,750	11,769,000	9,962,000	8,956,000	5,673,750	8,022,000	7,380,000	7,293,000	7,369,000	6,928,000	7,628,000	5,904,000
depreciation and amortization	20,919,000	22,613,000	22,632,000	23,281,000	22,891,000	22,600,000	15,748,000	14,697,000	14,686,000	15,194,000	15,207,000	14,690,000	14,700,000	14,484,000	14,167,000	13,764,000	14,557,000	13,684,000	11,346,000	11,324,000	10,898,000	8,434,750	11,358,000	11,198,000	11,183,000	8,762,000	9,473,000	9,472,000	16,103,000	6,264,000	8,548,000	8,313,000	8,195,000	5,226,500	7,099,000	7,101,000	6,706,000	5,812,000	5,966,000	5,956,000	4,609,000	2,111,000	2,047,000	1,415,000	1,327,000	1,282,000	1,187,000	706,000	703,000	437,172	381,699	146,523	166,386	171,452	25,749	30,933	30,866	29,868	35,670	40,519	41,944	39,033	41,000	42,546	45,421	41,113	33,308	33,333	29,246	9,159	11,759	12,309	9,773	10,491	17,993	28,600	32,916	32,709	30,725	27,109	27,457	24,489	25,464		26,043
contingent consideration fair value adjustment	-182,000	-5,727,000	-14,470,000	1,277,000	-12,092,000	-1,893,000	825,000	359,000	90,000	1,985,000	-2,555,000	1,035,000	961,000	1,624,000	2,476,000	-1,095,000	753,000
total operating expenses	198,574,000	212,293,000	191,573,000	197,479,000	170,928,000	194,952,000	168,851,000	132,871,000	117,118,000	124,928,000	113,881,000	104,145,000	96,891,000	92,412,000	88,816,000	86,768,000	83,672,000	84,652,000	55,623,000	64,178,000	51,476,000	56,921,000	50,177,000	59,777,000	57,616,000	52,637,000	44,009,000	45,065,000	48,485,000	45,677,000	40,589,000	40,005,000	39,946,000	39,907,000	38,833,000	37,770,000	32,003,000	36,907,000	30,604,000	26,143,000	14,889,000	11,767,000	11,521,000	11,102,000	9,232,000	10,265,000	9,188,000	9,107,000	7,404,000	7,072,507	7,025,931	9,926,373
operating income	38,888,000	34,767,000	36,240,000	13,892,000	26,194,000	-4,378,000	-20,519,000	5,169,000	20,312,000	6,726,000	17,948,000	12,402,000	9,895,000	1,820,000	-4,995,000	-12,913,000	-19,195,000	-23,723,000	-3,562,000	-15,553,000	3,045,000	-4,086,750	2,802,000	-11,307,000	-7,842,000	5,255,500	7,328,000	9,292,000	4,402,000	5,978,500	10,114,000	7,263,000	6,537,000	5,237,500	9,331,000	6,994,000	4,625,000	1,298,000	7,921,000	5,194,000	5,666,000	6,608,000	8,451,000	8,414,000	9,567,000	2,308,500	8,199,000	-2,460,000	3,495,000
yoy	48.46%	-894.13%	-276.62%	168.76%	28.96%	-165.09%	-214.32%	-58.32%	105.28%	269.56%	-459.32%	-196.04%	-151.55%	-107.67%	40.23%	-16.97%	-730.38%	480.49%	-227.12%	37.55%	-138.83%	-177.76%	-61.76%	-221.69%	-278.15%	-12.09%	-27.55%	27.94%	-32.66%	14.15%	8.39%	3.85%	41.34%	303.51%	17.80%	34.66%	-18.37%	-80.36%	-6.27%	-38.27%	-40.78%	186.25%	3.07%	-442.03%	173.73%
qoq	11.85%	-4.06%	160.87%	-46.96%	-698.31%	-78.66%	-496.96%	-74.55%	201.99%	-62.53%	44.72%	25.34%	443.68%	-136.44%	-61.32%	-32.73%	-19.09%	566.00%	-77.10%	-610.77%	-174.51%	-245.85%	-124.78%	44.19%	-249.22%	-28.28%	-21.14%	111.09%	-26.37%	-40.89%	39.25%	11.11%	24.81%	-43.87%	33.41%	51.22%	256.32%	-83.61%	52.50%	-8.33%	-14.26%	-21.81%	0.44%	-12.05%	314.42%	-71.84%	-433.29%	-170.39%
operating margin %	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
other income	-651,000	850,000	-853,000	1,739,000	198,000					-33,000	-39,000	-53,000		-42,000	37,000	764,000					-515,000			-116,000	10,000	-29,250	-33,000	46,000		-17,750	20,000			14,500	95,000		-18,000	-43,000	-21,000	-12,000	2,000	1,000	-28,000		68,000	88,000	82,000		29,000	-84,098.25	147,563								2,000	13,000																		13,750		55,000			32,000
unrealized gain on investment in equity securities	5,753,000	273,000	3,140,000	332,000	-921,000	-1,991,000	1,355,000	-2,712,000	9,655,000
interest expense	-3,769,000	-4,411,000	-4,727,000	-5,438,000	-5,484,000	-6,015,000	-2,331,000	-4,656,000	-4,600,000	-5,746,000	-6,398,000	-7,100,000	-7,696,000	-7,506,000	-7,264,000	-6,669,000	-6,613,000	-4,440,000	-2,497,000	-2,531,000	-2,454,000	-1,724,500	-2,510,000	-2,356,000	-2,032,000	-2,524,000	-3,336,000	-3,406,000	-3,354,000	-2,783,000	-3,768,000	-3,730,000	-3,634,000	-2,252,250	-3,052,000	-3,025,000	-2,932,000	-2,859,000	-2,856,000	-2,830,000	-2,782,000				-2,725,000					-98		-374,476
income before income tax expense	40,221,000	16,078,000	33,800,000	10,525,000	19,987,000	-2,112,500	-31,498,000	-2,287,000	25,335,000
income tax expense	10,729,000	3,989,000	7,183,000	1,976,000	4,306,000	-3,486,000	-7,332,000		7,128,000																																																																		-75,000		75,000
net income	29,492,000	27,490,000	26,617,000	8,549,000	15,681,000	-10,276,000	-24,166,000	-2,287,000	18,207,000	1,155,000	9,940,000	6,245,000	1,439,000	-4,243,000	-8,600,000	-14,923,000	-20,130,000	-24,136,000	-4,447,000	-14,106,000	86,000	-4,728,250	434,000	-12,336,000	-7,011,000	2,732,250	3,895,000	6,585,000	449,000	2,516,000	5,037,000	2,777,000	2,250,000	2,138,250	4,720,000	2,681,000	1,152,000	-1,080,000	2,543,000	1,125,000	1,346,000	2,876,000	4,559,000	3,571,000	4,369,000	21,005,000	6,746,000	-2,363,000	3,359,000	3,432,929	1,191,043	-4,583,266	-2,290,649	-3,987,592	-6,121,815	-7,344,116	-10,264,477	-6,648,401	-12,733,691	-14,975,231	-17,250,676	-13,271,519	-11,589,711	-10,794,351	-10,540,419	-32,486,130	-6,370,556	-4,620,701	-4,050,612	-1,165,211	-6,585,084	-6,048,067	-3,626,638	-1,673,629	-1,693,044	-2,400,309	-1,817,018	8,989,456	-745,061	-2,224,900
yoy	88.07%	-367.52%	-210.14%	-473.81%	-13.87%	-989.70%	-343.12%	-136.62%	1165.25%	-127.22%	-215.58%	-141.85%	-107.15%	-82.42%	93.39%	5.79%	-23506.98%	410.46%	-1124.65%	14.35%	-101.23%	-273.05%	-88.86%	-287.33%	-1661.47%	8.59%	-22.67%	137.13%	-80.04%	17.67%	6.72%	3.58%	95.31%	-297.99%	85.61%	138.31%	-14.41%	-137.55%	-44.22%	-68.50%	-69.19%	-86.31%	-32.42%	-251.12%	30.07%	511.87%	466.39%	-48.44%	-246.64%	-186.09%	-119.46%	-37.59%	-77.68%	-40.02%	-51.92%	-50.96%	-40.50%	-49.90%	9.87%	38.73%	63.66%	-59.15%	81.93%	133.61%	160.22%	2688.00%	-3.26%	-23.60%	11.69%	-30.38%	288.95%	151.97%	99.59%	-118.62%	127.24%	7.88%
qoq	7.28%	3.28%	211.35%	-45.48%	-252.60%	-57.48%	956.67%	-112.56%	1476.36%	-88.38%	59.17%	333.98%	-133.91%	-50.66%	-42.37%	-25.87%	-16.60%	442.75%	-68.47%	-16502.33%	-101.82%	-1189.46%	-103.52%	75.95%	-356.60%	-29.85%	-40.85%	1366.59%	-82.15%	-50.05%	81.38%	23.42%	5.23%	-54.70%	76.05%	132.73%	-206.67%	-142.47%	126.04%	-16.42%	-53.20%	-36.92%	27.67%	-18.27%	-79.20%	211.37%	-385.48%	-170.35%	-2.15%	188.23%	-125.99%	100.09%	-42.56%	-34.86%	-16.64%	-28.45%	54.39%	-47.79%	-14.97%	-13.19%	29.98%	14.51%	7.37%	2.41%	-67.55%	409.94%	37.87%	14.07%	247.63%	-82.31%	8.88%	66.77%	116.69%	-1.15%	-29.47%	32.10%	-120.21%	-1306.54%	-66.51%
net income margin %	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
dividends on series a convertible preferred stock			-344,000	-407,000	-406,000	-406,000	-406,000	-407,000	-406,000	-406,000	-406,000	-407,000	-406,000	-407,000	-406,000	-407,000	-405,000
net income available to common shareholders	29,492,000	27,490,000	26,273,000	8,142,000	15,275,000	-10,682,000	-24,572,000	-2,694,000	17,801,000	749,000	9,534,000	5,838,000	1,033,000				-20,535,000
basic and diluted income per share:
basic income per share	1.31	1.24	1.19	0.37	0.7	-0.55	-1.27	-0.14	0.84	0.02	0.46	0.3	0.06
diluted income per share	1.28	1.17	1.13	0.36	0.69	-0.55	-1.27	-0.14	0.82	0.02	0.45	0.29	0.06
basic weighted-average shares outstanding	20,914	20,053	20,074	19,834	19,607	19,318	19,404	19,321	19,099	18,001	18,883	17,688	16,392	16,260	16,303	16,272	16,137	12,596	12,107	12,085	12,004		11,991	11,967	11,902		11,879	11,851	11,747		11,706	11,679	11,589		11,553	11,546	11,527	11,445	11,465	11,402	11,395	11,370	11,384	11,344	11,326	10,941	11,235	11,233	9,991
diluted weighted-average shares outstanding	21,544	21,228	21,093	20,308	20,046	19,318	19,404	19,321	19,422	18,194	19,125	17,855	16,531	16,260	16,303	16,272	16,137	12,596	12,107	12,085	12,017		12,003	11,967	11,902		12,085	12,269	11,823		11,804	11,789	11,706		11,677	11,667	11,653	11,573	11,625	11,541	11,489	11,557	11,563	11,549	11,562	11,053	11,302	11,233	10,001
loss on disposal of assets		87,000	295,000
intangible asset impairment charge			767,000													112,000
other expense						-663,750	-2,535,000	-88,000	-32,000				-34,000				-89,000	-2,690,000	-1,071,000	-67,000		-83,750	-229,000						-130,000			-30,000	-61,000			-19,000												-39,000				-433,956
loss on extinguishment of debt							-7,468,000
gain on sale of building									-5,347,000
restructuring activities												2,000	1,130,000	1,568,000	1,541,000	2,570,000
income before income tax benefit										4,731,250	11,511,000	5,249,000	2,165,000
income tax benefit										-325,250	-1,571,000	996,000	-726,000																																					20,713	82,852			209	121,791
legal settlement expense																		350,000		8,400,000
purified cortrophin gel pre-launch charges																			227,000
loss before benefit for income taxes														-5,728,000	-12,222,000	-18,818,000				-18,151,000
benefit for income taxes														1,485,000	3,622,000	3,895,000	5,767,000	6,717,000	2,683,000	4,045,000	10,000	-1,253,000	371,000	1,443,000	2,853,000	2,817,000	-64,000	653,000																		10,945,000	-1,545,000	133,000
net loss available to common shareholders														-4,650,000	-9,006,000	-15,330,000
basic and diluted loss per share:
basic loss per share														-0.29	-0.55	-0.94				-1.17
diluted loss per share														-0.29	-0.55	-0.94				-1.17
income before benefit for income taxes																	-25,897,000	-30,853,000	-7,130,000		76,000	-5,895,000	63,000	-13,779,000	-9,864,000	2,702,250	3,959,000	5,932,000
basic and diluted earnings per share:
basic earnings per share																	-1.27	-1.87	-0.37		0.01	-0.395	0.04	-1.03	-0.59	0.228	0.32	0.55	0.04	0.213	0.43	0.24	0.19	0.185	0.41	0.23	0.1	-0.1	0.22	0.1	0.12	0.273	0.4	0.31	0.38	0.178	0.59	-0.21	0.33
diluted earnings per share																	-1.27	-1.87	-0.37		0.01	-0.395	0.04	-1.03	-0.59	0.223	0.32	0.53	0.04	0.213	0.42	0.23	0.19	0.183	0.4	0.23	0.1	-0.09	0.22	0.1	0.12	0.268	0.39	0.31	0.38	0.175	0.59	-0.21	0.33
cortrophin pre-launch charges																				515,000	38,000	2,068,750	37,000	3,636,000	4,602,000	48,750	195,000
operating expenses:
income before provision for income taxes																													918,000	3,177,750	6,366,000	3,503,000	2,842,000	2,999,750	6,374,000	3,950,000	1,675,000	2,570,500	5,044,000	2,352,000	2,886,000	4,558,000	5,657,000		6,910,000	2,329,750	8,291,000	-2,496,000	3,524,000
provision for income taxes																													-469,000	-661,750	-1,329,000	-726,000	-592,000	-861,500	-1,654,000	-1,269,000	-523,000	-1,317,000	-2,501,000	-1,227,000	-1,540,000	-1,433,250	-1,098,000		-2,541,000				-165,000
selling, general and administrative																																										3,925,250	5,399,000	5,551,000	4,751,000	4,742,000	4,057,000	5,433,000	3,703,000	12,126,818	1,750,734	1,457,845
interest income																																										-2,060,000	-2,766,000	-2,749,000		3,250	10,000	3,000					1,860	1,325	1,877	1,431	1,992	1,618	1,516	1,711	3,245	1,366.5	5,466
income before provision for/benefit from income taxes																																												5,665,000
benefit from income taxes																																												-2,094,000
net income from continuing operations																																														21,005,000	6,746,000			3,388,266	1,040,706	-4,583,266
discontinued operation																																																			0.02
gain on discontinued operation, net of provision for income taxes
computation of income from continuing operations attributable
to common stockholders and participating securities:
preferred stock dividends																																																		-801		-2,370,028
income from continuing operations attributable to common stockholders and participating securities																																														21,005,000	6,746,000
continuing operations																																														1.9	0.59			1.35	0.11	-6.02
computation of income attributable to common stockholders:
income attributable to common stockholders																																																-2,363,000	3,359,000
salaries and benefits																																																		2,174,909.5	1,729,066	5,713,504
freight																																																		56,047.25	81,416	72,777
operating income from continuing operations																																																		3,459,823	810,291	-3,774,834
net income from continuing operations before income tax benefit																																																		-841,279.5	957,854	-4,583,266
gain on discontinued operation, net of tax																																																		37,584.25	150,337
computation of income from continuing operationsattributable to common stockholders:
income from continuing operations attributable to common stockholders																																																		-2,064,116.25	1,040,706
basic and diluted income per share																																																		1.35	0.13
basic and diluted weighted-average shares outstanding																																																		5,071	9,480,206	1,155,093
discontinued operations
gain on discontinued operations, net of tax
computation of income from continuing operations attributable to common stockholders:
loss from continuing operations attributable to common stockholders																																																				-6,953,294
basic and diluted loss per share																																																				-6.02
revenue
yoy
qoq
royalty revenue																																																					145,040	83,290.75	110,383	108,780	114,000	55,196.75	82,784	81,003	57,000	26,665	51,331		2,228,004	1,051,066		85,449	5,485	3,781	3,734	11,081	15,404	2,009	14,063	52,928
revenue - sum																																																					145,040	83,290.75	110,383	108,780	114,000	80,196.75	182,784		57,000	582,801.25	51,331		2,279,874	48,520.75	10,492	115,163	68,428	42,769.5	82,212	25,869	62,997	40,961.75	43,793	69,446	50,608	100,063.5	140,324	175,251	84,679	96,971	87,106		45,596
expenses
general and administration																																																					1,949,114	2,902,289	1,546,864	1,948,995	1,831,852	1,724,147	1,675,268	1,989,103	1,593,557	1,367,131	1,534,417	1,540,200	1,498,252	1,629,786	1,506,056	1,208,956	1,029,202	767,535	1,438,816	1,593,156	1,325,493	1,119,241	1,027,194	1,181,377	771,589	-377,183	210,552	1,328,612	2,223,019	849,920	704,966		775,174
expenses - sum																																																					3,087,549	4,967,379.25	5,445,349	7,378,233	7,045,935	10,714,214.5	13,210,991	13,145,945	16,499,921	8,192,788.25	11,291,508	10,240,352	11,239,293	3,811,900.25	6,381,048		4,130,688	4,081,460.5	6,773,047	5,539,583	4,013,212	1,707,587.25	2,190,951	2,700,243	1,939,155	1,721,882.75	1,007,869		3,409,353
other
convertible note fair value adjustment																																																								15,953			463,000
gain on sale of intellectual property																																																					1,000,000
basic and diluted net loss per share																																																					-0.09	-0.285	-0.27	-0.36	-0.09	-0.12	-0.12	-0.16	-0.2	-0.128	-0.16	-0.17	-0.19	-0.133	-0.21	-0.17	-0.15	-0.15	-0.24
weighted-average number of shares outstanding																																																					24,487,451		22,921,176	20,202,737	116,266,613		104,439,220	93,985,347	84,764,512		71,194,180		56,312,814	33,952	30,434,050		27,434,050		27,380,217			25,486
licensing revenue																																																										25,000	100,000											3,374,909		4,546	4,545	149,000	9,091	6,818	34,091
loss before income tax benefit
grant revenue																																																														130			51,870	12,851	10,492	29,714	62,943	8,028	21,082	10,242	25,648	12,144	20,639	9,700	16,517
investment impairment loss
other revenue																																																																						223,204	57,396		17,400
acquisition related costs																																																																		367,616.75	1,470,467
licensing expense																																																														250			268,750
fair value adjustment																																																															103,000
weighted average number of shares outstanding																																																																64,607,893				27,434,050		27,307								21,191				19,392,116
other - impairment of short term investments																																																																						165,050		660,200
other - interest income																																																																		2,912			11,648	138,793.75	105,751	125,847	323,577	189,032.75	379,114	230,488	146,529	72,205.25	122,484	70,158	96,179	96,923	104,390		101,926
net loss before income tax expense
net loss before income
tax expense																																																																								-6,048,067	-3,626,638	-1,477,592.75	-1,768,044	-2,400,309	-1,742,018
basic and diluted net loss
per share																																																																								-0.22	-0.13	-0.06	-0.06	-0.1	-0.08	-0.075	-0.03	-0.11
weighted average number
of shares outstanding																																																																								27,232,272	27,185,893	6,232,170.5	27,137,431	23,870,950	23,367,493	5,118,095.75	22,412,189	19,551,980	19,426,895	4,847,490	19,399,086		19,385,086
see accompanying notes to the condensed financial statements.
see accompanying notes to the financial statements.
stock compensation expense																																																																												142,905	220,798
licensing income																																																																														25,568.25	34,091	34,091	34,091	34,091	11,364
grant income																																																																														60,745.25	106,233	86,160	50,588	62,880	43,742		45,596
loss on disposal of capital assets
costs of acquisition of structured biologicals inc.
purchassed in-process research and development
provision for contingencies																																																																																	140,000
purchased in-process research
and development
purchased in-process research and development
costs of acquisition of structured
biologicals inc.
biologicals inc.-
and development-

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30

assets
current assets
cash and cash equivalents	311,176,000	285,585,000	262,610,000	217,797,000	149,802,000	144,861,000	144,982,000	240,110,000	228,597,000	221,121,000	193,078,000	161,707,000	67,757,000	48,228,000	56,281,000	63,385,000	76,911,000	100,300,000	15,254,000	24,261,000	25,073,000	7,864,000	17,900,000	27,702,000	20,414,000	62,332,000	59,673,000	40,589,000	38,233,000	43,008,000	44,136,000	54,994,000	51,970,000	31,144,000	18,031,000	8,369,000	10,826,000	27,365,000	16,155,000	15,014,000	77,747,000	154,684,000	150,913,000	166,731,000	165,563,000	169,037,000	35,050,000	52,961,000	51,373,000	11,105,000	10,929,806	12,594,927	29,388,772	34,794,341	38,049,095	42,417,045	49,473,732	57,225,234	69,600,199	37,126,006	51,349,021	38,155,251	35,526,017	46,382,112	41,163,001	29,858,465	13,169,258	5,985,823	10,162,346	11,760,920	5,700,697	10,325,577	13,106,123	15,648,948	25,402,564	27,382,168	11,290,742	7,653,852	366,174	133,605	70,189	310,643	254,142	379,523
restricted cash	36,000	36,000	36,000	36,000	34,000	33,000	35,000								5,003,000	5,001,000	5,000,000	5,001,000	5,001,000	5,001,000	5,000,000	5,003,000	5,003,000	5,002,000	5,002,000	5,029,000	5,025,000	5,018,000	5,008,000	5,021,000	5,014,000	5,007,000	5,002,000	5,006,000	5,004,000	5,002,000	5,001,000	5,002,000	5,001,000	5,001,000											2,260,100	2,260,100	2,260,100
accounts receivable	255,432,000																																																		9,515,096	6,427,506												53,156	132,748	64,645	38,271	117,333	356,751	229,775	82,531	21,292	30,218	14,566	3,599,764	3,577,339	3,514,711	10,510,529
inventories	143,468,000	143,067,000	146,475,000	138,315,000	137,408,000	136,782,000	148,042,000	125,448,000	113,837,000	111,196,000	106,590,000	104,323,000	103,654,000	105,355,000	95,893,000	92,545,000	83,155,000	81,693,000	61,684,000	67,634,000	59,927,000	60,803,000	59,195,000	52,563,000	52,902,000	48,163,000	46,174,000	45,296,000	42,032,000	40,503,000	40,006,000	37,756,000	34,294,000	37,727,000	38,478,000	42,307,000	45,893,000	26,183,000	28,261,000	25,052,000	13,922,000	13,387,000	13,741,000	12,701,000	10,737,000	7,518,000	7,346,000	5,912,000	5,090,000	3,518,000	2,809,160	2,584,686
prepaid expenses and other current assets	22,087,000	23,189,000	18,551,000	15,110,000	23,326,000	17,975,000	17,475,000	14,001,000	16,050,000	17,400,000	10,690,000	8,248,000	6,874,000	8,387,000	4,972,000	6,026,000	7,726,000	7,589,000	4,702,000	4,881,000	5,922,000	5,861,000	3,358,000	3,117,000	2,967,000	3,995,000	5,025,000	3,311,000	4,157,000	4,524,000	5,004,000	1,768,000	2,267,000	2,784,000	4,847,000	2,676,000	3,565,000	3,564,000	2,653,000	4,046,000	1,252,000	1,453,000	1,985,000	1,615,000	1,546,000	1,983,000
investment in equity securities	14,885,000	9,131,000	8,859,000	5,718,000	5,386,000	6,307,000	8,298,000	6,943,000	9,655,000
total current assets	747,084,000	753,117,000	698,402,000	602,630,000	536,290,000	527,684,000	521,297,000	555,460,000	540,557,000	519,816,000	497,220,000	459,311,000	364,753,000	344,261,000	309,377,000	322,399,000	301,399,000	321,775,000	191,384,000	191,799,000	182,798,000	170,321,000	165,819,000	156,544,000	158,662,000	187,695,000	182,386,000	168,912,000	151,832,000	152,877,000	156,793,000	152,367,000	143,394,000	131,605,000	125,582,000	112,856,000	106,981,000	103,007,000	95,475,000	79,824,000	116,552,000	192,583,000	197,522,000	208,948,000	202,993,000	203,478,000	57,565,000	67,160,000	67,936,000	27,716,000	26,094,759	24,118,984
non-current assets
property and equipment	67,115,000	62,476,000	63,560,000	59,247,000	58,179,000	56,863,000	56,704,000	51,640,000	48,526,000	44,593,000	44,189,000	44,371,000	70,553,000	75,958,000	72,935,000	71,042,000	77,677,000	75,627,000	60,816,000	60,336,000	59,541,000	41,269,000	40,444,000	39,937,000	40,353,000	40,551,000	39,754,000	38,953,000	38,425,000	38,090,000	37,418,000	22,842,000	21,882,000	20,403,000	17,387,000	14,966,000	12,897,000	10,998,000	9,716,000	8,911,000	8,415,000	7,131,000	5,833,000	5,249,000	5,281,000	5,223,000				4,537,000				166,386	1,184,764	862,439	884,301	861,364	854,989	1,132,519	812,962	635,776	646,500	683,800	710,395	747,979	720,403	752,970	786,303	814,894	529,301	162,481	59,748	54,896	43,783	58,520	104,124	137,040	169,529	164,906	188,629	215,566	218,555	241,806
deferred tax assets	66,555,000
intangible assets	467,161,000	479,526,000	499,817,000	520,320,000	538,495,000	541,834,000	569,825,000	183,078,000	196,044,000	209,009,000	219,828,000	230,299,000	238,791,000	251,635,000	264,237,000	269,593,000	281,573,000	294,122,000	170,141,000	180,199,000	178,859,000	188,511,000	198,620,000	205,745,000	215,619,000	180,388,000	188,372,000	196,697,000	205,100,000	201,604,000	209,544,000	217,484,000	221,917,000	229,790,000	189,829,000	196,624,000	203,459,000	175,792,000	188,949,000	194,674,000	147,386,000	66,397,000	68,291,000	44,174,000	45,408,000	42,067,000	43,188,000	21,800,000	22,360,000	10,409,000	10,712,273	10,960,000
goodwill	62,480,000	62,480,000	62,480,000	60,533,000	60,662,000	59,990,000	60,426,000	28,221,000	28,221,000	28,221,000	28,221,000	28,221,000	28,221,000	28,221,000	28,221,000	28,221,000	28,188,000	27,888,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	3,580,000	4,180,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,000	1,838,309	1,838,309
other non-current assets	11,575,000																	2,205,000	626,000	720,000	833,000	802,000	985,000	1,095,000	1,110,000	1,220,000	1,656,000	1,789,000	1,903,000
total assets	1,421,970,000	1,440,377,000	1,408,152,000	1,343,001,000	1,292,428,000	1,283,697,000	1,287,377,000	920,753,000	914,524,000	904,422,000	889,914,000	859,341,000	765,224,000	760,087,000	739,110,000	751,334,000	744,846,000	771,598,000	470,454,000	480,159,000	463,843,000	461,190,000	462,581,000	465,391,000	482,232,000	456,789,000	456,775,000	446,906,000	434,390,000	430,604,000	439,443,000	424,177,000	418,019,000	412,138,000	370,469,000	359,219,000	357,138,000	322,864,000	319,379,000	307,999,000	291,588,000	285,265,000	283,276,000	270,121,000	265,985,000	263,709,000	107,637,000	95,423,000	96,652,000	44,500,000	43,285,828	41,658,023
liabilities and stockholders’ equity
current liabilities
current debt	19,298,000
accounts payable	69,694,000	62,583,000	69,795,000	54,569,000	53,058,000	45,656,000	60,890,000	48,681,000	49,430,000	36,683,000	34,077,000	28,505,000	32,687,000	29,305,000	18,992,000	27,641,000	22,059,000	22,967,000	11,513,000	12,977,000	13,769,000	11,261,000	13,460,000	14,209,000	12,485,000	14,606,000	10,953,000	9,809,000	10,519,000	8,884,000	7,257,000	7,949,000	4,886,000	3,630,000	5,821,000	3,153,000	4,785,000	3,389,000	4,730,000	4,961,000	3,040,000	2,066,000	2,633,000	1,325,000	2,288,000	2,654,000	3,059,000	1,731,000	2,660,000	1,429,000	2,086,847	1,634,788	164,352	1,128,644	2,004,814	3,835,756	3,281,705	3,150,677	6,041,891	6,348,948	8,503,790	4,864,217	4,522,800	4,719,457	4,002,557	2,440,096	3,529,203	2,550,227	2,429,446	3,182,089	3,420,066	2,619,915	2,301,248	710,575	559,380	888,751	643,845	621,818	318,254	669,734	1,380,026	1,139,566	518,473	782,495
accrued royalties	33,926,000	48,497,000	51,247,000	36,030,000	23,713,000	22,626,000	23,447,000	20,357,000	15,475,000	16,276,000	11,975,000	9,885,000	8,957,000	9,307,000	6,585,000	6,295,000	4,998,000	6,225,000	3,996,000	4,688,000	5,310,000	6,407,000	6,088,000	6,004,000	6,285,000	5,084,000	5,527,000	6,265,000	5,440,000	8,456,000	7,455,000	8,219,000	11,361,000	12,164,000	11,741,000	11,255,000	10,331,000	11,956,000	11,769,000	8,110,000	4,632,000	606,000
accrued compensation and related expenses	16,091,000	37,897,000	33,221,000	32,933,000	22,297,000	37,725,000	29,777,000	16,111,000	9,526,000	23,786,000	15,328,000	11,493,000	13,051,000	10,312,000	7,745,000	5,682,000	3,265,000	8,522,000	4,539,000	4,319,000	5,533,000	6,231,000	5,993,000	5,349,000	3,151,000	3,736,000	3,494,000	2,133,000	2,454,000	3,524,000	2,773,000	1,410,000	1,495,000	2,306,000	2,009,000	1,227,000	1,135,000	1,631,000	1,426,000	1,071,000	722,000	1,188,000	1,019,000	844,000	513,000	1,348,000
accrued government rebates	38,417,000	43,154,000	37,032,000	32,866,000	22,644,000	18,714,000	10,693,000	12,324,000	9,509,000	12,168,000	10,923,000	11,971,000	8,607,000	10,872,000	8,745,000	9,440,000	4,557,000	5,492,000	11,713,000	8,740,000	8,672,000	7,826,000	11,678,000	9,717,000	8,030,000	8,901,000	9,184,000	10,943,000	8,552,000	8,974,000	9,014,000	5,256,000	6,471,000	7,930,000	5,755,000	3,534,000	4,655,000	5,891,000
income taxes payable	5,297,000	1,291,000		3,294,000	14,188,000	6,749,000			11,402,000	8,164,000	594,000
returned goods reserve	43,052,000	49,504,000	50,005,000	48,683,000	42,464,000	39,274,000	37,068,000	33,897,000	32,853,000	29,678,000	31,438,000	29,798,000	34,108,000	33,399,000	33,984,000	34,899,000	35,554,000	35,831,000	32,229,000	31,904,000	28,944,000	27,155,000	23,250,000	20,003,000	17,614,000	16,595,000	15,945,000	14,656,000	13,559,000	12,552,000	10,840,000	9,764,000	9,020,000	8,274,000	8,317,000	7,558,000	5,776,000	5,756,000	4,099,000	3,309,000	2,666,000	2,648,000	1,889,000	1,719,000	1,817,000	1,445,000	1,178,000	951,000	849,000	736,000	457,890	349,763
accrued expenses and other	13,735,000	16,803,000	13,951,000	14,761,000	12,029,000	13,735,000	17,814,000	6,917,000	7,430,000	5,606,000	5,228,000	5,338,000	4,804,000	5,394,000	4,726,000	11,505,000	8,133,000	7,563,000	4,893,000	11,582,000	2,381,000	2,456,000	2,534,000	3,066,000	4,378,000	2,362,000	3,368,000	2,423,000	3,074,000	1,707,000	2,818,000	1,863,000	2,612,000	1,571,000	2,741,000	1,565,000	2,087,000	927,000	2,016,000	770,000	1,727,000	617,000	2,221,000	1,170,000	1,897,000	1,269,000
total current liabilities	239,510,000	278,112,000	270,555,000	236,835,000	201,815,000	193,680,000	189,933,000	139,978,000	136,889,000	145,477,000	134,352,000	122,865,000	125,825,000	99,439,000	81,627,000	96,312,000	79,532,000	87,537,000	84,872,000	89,454,000	82,768,000	78,565,000	75,900,000	79,088,000	79,356,000	61,676,000	170,707,000	166,794,000	165,068,000	165,549,000	46,902,000	39,678,000	39,650,000	39,228,000	36,384,000	28,292,000	32,425,000	31,948,000	30,491,000	24,730,000	16,211,000	11,756,000	12,190,000	6,949,000	9,073,000	13,233,000	8,145,000	3,828,000	4,560,000	3,538,000	6,597,023	6,163,213																							2,234,868	2,610,549	2,430,717	4,299,610	1,662,982	2,303,623	2,734,762	2,666,034	1,504,865
non-current liabilities
debt	285,996,000
convertible notes	308,466,000
contingent consideration	9,248,000
other non-current liabilities	16,450,000	12,164,000	11,270,000	6,696,000	7,020,000	5,781,000	6,944,000	4,679,000	5,055,000	4,809,000	5,259,000	4,731,000	1,202,000											17,080,000	13,611,000	6,514,000	8,065,000	6,768,000	3,109,000
total liabilities	859,670,000	899,653,000	902,335,000	881,394,000	848,958,000	855,167,000	856,579,000	440,143,000	437,711,000	446,823,000	435,203,000	424,869,000	425,742,000	421,547,000	402,435,000	414,376,000	398,752,000	412,858,000	279,051,000	288,242,000	260,131,000	265,490,000	267,481,000	274,047,000	281,061,000	243,998,000	243,645,000	239,250,000	234,678,000	233,341,000	246,978,000	239,067,000	238,375,000	237,382,000	187,668,000	182,673,000	184,926,000	153,216,000	150,549,000	144,223,000	131,410,000	125,183,000	127,383,000	120,621,000	121,245,000	123,924,000							9,325,736	10,593,665	10,922,066	16,373,638	16,578,542	24,564,463	30,742,051	31,233,334	30,669,399	25,619,528	25,459,464	25,157,583	24,310,432	20,606,534												4,299,610	1,705,982	2,325,123	2,790,353	2,755,716	1,607,138
commitments and contingencies
stockholders’ equity
common stock, 0.0001 par value...	3,000	3,000	3,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000		954
class c special stock, 0.0001 par value...
preferred stock, 0.0001 par value...
treasury stock	-53,004,000	-33,249,000	-32,638,000	-31,594,000	-31,043,000	-21,040,000	-20,722,000	-20,042,000	-18,742,000	-10,081,000	-9,850,000	-9,180,000	-8,643,000	-5,094,000	-4,975,000	-4,736,000	-4,253,000	-3,135,000	-3,135,000	-3,062,000	-2,594,000	-2,246,000	-2,246,000	-2,246,000	-1,211,000	-723,000	-723,000	-723,000		-659,000	-659,000	-659,000	-250,000	-259,000	-259,000	-259,000								-113,000					-68,000	-68,000	-432,562	-432,562
additional paid-in capital	608,429,000	596,036,000	586,230,000	541,899,000	531,055,000	519,653,000	510,899,000	532,497,000	523,628,000	514,103,000	506,513,000	495,488,000	408,395,000	403,901,000	399,396,000	395,043,000	391,084,000	387,844,000	222,211,000	219,403,000	216,223,000	214,354,000	211,792,000	209,409,000	203,505,000	200,800,000	197,470,000	194,867,000	189,971,000	186,812,000	186,532,000	184,531,000	181,649,000	179,020,000	177,436,000	175,901,000	173,989,000	172,563,000	170,665,000	168,154,000	165,681,000	164,431,000	163,118,000	161,397,000	160,095,000	159,509,000	140,221,000	139,070,000	137,272,000	89,501,000	89,024,878	89,021,927
retained earnings	6,393,000																								10,565,000	17,584,000	22,419,000	18,524,000	11,939,000
accumulated other comprehensive income, net of tax	479,000	1,033,000	2,811,000	3,312,000	3,610,000	5,344,000	5,366,000	8,328,000	9,406,000	8,857,000	14,076,000	13,726,000	11,131,000	12,168,000	10,039,000	5,430,000	2,712,000														533,000	216,000
total stockholders’ equity	562,300,000	540,724,000	505,817,000	436,757,000	418,620,000	403,680,000	405,948,000	455,760,000	451,963,000	432,749,000	429,861,000	409,622,000	314,632,000	313,690,000	311,825,000	312,108,000	321,244,000	333,890,000	191,403,000	191,917,000	203,712,000	195,700,000	195,100,000	191,344,000																															32,289,680
total liabilities and stockholders’ equity	1,421,970,000																		470,454,000	480,159,000	463,843,000	461,190,000	462,581,000	465,391,000
accounts receivable, net of 171,803 and 127,824 of adjustments for chargebacks and other allowances at december 31, 2025 and 2024, respectively		281,082,000
prepaid income taxes		11,027,000	9,254,000				6,104,000	2,867,000				4,088,000	3,735,000	3,827,000	3,778,000	2,013,000	1,982,000	3,667,000	3,030,000	2,375,000			1,621,000			1,076,000	814,000	3,442,000				1,734,000	62,000	1,162,000	2,052,000	3,991,000			929,000	150,000	1,150,000	1,127,000	972,000	1,022,000
deferred tax assets, net of deferred tax liabilities and valuation allowance		69,072,000	71,396,000	92,025,000	88,489,000	85,106,000	67,661,000	89,506,000	87,607,000	90,711,000	84,389,000	81,500,000	80,956,000	81,363,000	77,340,000	76,587,000	73,539,000	67,936,000	60,196,000	58,526,000	52,006,000	51,704,000	48,130,000	53,488,000	57,906,000	38,326,000	36,002,000	31,957,000	28,542,000	27,964,000	25,082,000	23,590,000
derivatives and other non-current assets		13,706,000	12,497,000	8,246,000	10,313,000	12,220,000	11,464,000	12,848,000	13,569,000	12,072,000	16,067,000	15,639,000	9,228,000	11,361,000	12,102,000	5,762,000	2,434,000
liabilities, mezzanine equity, and stockholders’ equity
current debt, net of deferred financing costs		17,268,000	15,241,000	13,216,000	11,193,000	9,172,000	7,152,000	850,000	850,000	850,000	850,000	850,000	850,000	850,000	850,000	850,000	850,000	850,000	15,927,000	15,182,000	14,438,000	13,243,000	12,785,000	12,329,000	11,872,000
income taxes payable - foreign		948,000
current contingent consideration		167,000	63,000	483,000	229,000	29,000	1,283,000	841,000	414,000	12,266,000	23,939,000	25,025,000	22,761,000
non-current debt, net of deferred financing costs and current component		291,840,000	297,677,000	301,484,000	305,294,000	309,108,000	312,918,000	284,394,000	284,607,000	284,819,000	285,032,000	285,244,000	285,457,000	285,669,000	285,882,000	286,095,000	286,307,000	286,520,000	186,063,000	189,525,000	168,985,000	172,443,000	175,161,000	177,879,000	188,094,000
non-current convertible notes, net of deferred financing costs		307,927,000	307,392,000	306,862,000	306,335,000	305,812,000	305,293,000
accrued licensor payments due			4,062,000	11,428,000	11,068,000	20,961,000
non-current contingent consideration, net of current		9,610,000	11,379,000	18,089,000	17,426,000	19,825,000				11,718,000
mezzanine equity
convertible preferred stock, series a, 0.0001 par value...				24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000	24,850,000
accumulated deficit		-23,099,000	-50,589,000	-76,862,000	-85,004,000	-100,279,000	-89,597,000	-65,025,000	-62,331,000	-80,132,000	-80,880,000	-90,414,000	-96,252,000	-97,286,000	-92,636,000	-83,630,000	-68,300,000	-47,765,000	-23,439,000	-18,992,000	-4,886,000												-1,756,000	-4,006,000			-1,778,000	-2,916,000	-1,836,000	-4,379,000	-5,504,000	-4,350,000	-7,226,000	-11,785,000	-15,356,000	-19,725,000	-40,730,000	-47,476,000	-45,113,000	-48,472,000	-51,904,465	-53,095,509														-119,434,428						-64,156,187	-58,108,120	-54,481,482	-52,807,418	-51,114,374	-48,714,065
total liabilities, mezzanine equity, and stockholders’ equity		1,440,377,000	1,408,152,000	1,343,001,000	1,292,428,000	1,283,697,000	1,287,377,000	920,753,000	914,524,000	904,422,000	889,914,000	859,341,000	765,224,000	760,087,000	739,110,000	751,334,000	744,846,000	771,598,000
accounts receivable, net of 125,165 and 127,824 of adjustments for chargebacks and other allowances at september 30, 2025 and december 31, 2024, respectively			252,617,000
accounts receivable, net of 120,421 and 127,824 of adjustments for chargebacks and other allowances at june 30, 2025 and december 31, 2024, respectively				225,654,000
accounts receivable, net of 139,655 and 127,824 of adjustments for chargebacks and other allowances at march 31, 2025 and december 31, 2024, respectively					220,334,000
accounts receivable, net of 127,824 and 97,262 of adjustments for chargebacks and other allowances at december 31, 2024 and 2023, respectively						221,726,000
assets held for sale										8,020,000	8,020,000	8,020,000	8,020,000	8,020,000	8,020,000	8,020,000
accounts receivable, net of 91,008 and 97,262 of adjustments for chargebacks and other allowances at september 30, 2024 and december 31, 2023, respectively							196,361,000
accrued licensor payment							1,809,000
non-current contingent consideration							20,175,000	11,092,000	11,160,000		10,560,000	12,029,000	13,258,000	35,058,000	33,434,000	30,958,000	32,053,000	31,000,000
accrued licensor payment, net of current							21,316,000
accounts receivable, net of 102,784 and 97,262 of adjustments for chargebacks and other allowances at june 30, 2024 and december 31, 2023, respectively								166,091,000
accounts receivable, net of 91,825 and 97,262 of adjustments for chargebacks and other allowances at march 31, 2024 and december 31, 2023, respectively									172,418,000
current restricted cash														5,006,000
accounts receivable, net of 97,262 and 161,052 of adjustments for chargebacks and other allowances at december 31, 2023 and 2022, respectively										162,079,000
accounts receivable, net of 97,774 and 161,052 of adjustments for chargebacks and other allowances at september 30, 2023 and december 31, 2022, respectively											178,842,000
accounts receivable, net of 89,427 and 161,052 of adjustments for chargebacks and other allowances at june 30, 2023 and december 31, 2022, respectively												172,925,000
accounts receivable, net of 112,950 and 161,052 of adjustments for chargebacks and other allowances at march 31, 2023 and december 31, 2022, respectively													174,713,000
accumulated depreciation													-27,278,000	-32,712,000	-30,105,000	-27,271,000	-24,964,000	-22,956,000	-21,290,000	-20,002,000	-18,774,000
accounts receivable, net of 161,052 and 105,260 of adjustments for chargebacks and other allowances at december 31, 2022 and 2021, respectively														165,438,000
non-current restricted cash
derivatives and other non-current liabilities														1,381,000	1,492,000	1,011,000	860,000	7,801,000	8,116,000	9,263,000	8,378,000	14,482,000	16,420,000
accounts receivable, net of 111,000 and 105,260 of adjustments for chargebacks and other allowances at september 30, 2022 and december 31, 2021, respectively															140,433,000
accounts receivable, net of 150,428 and 105,260 of adjustments for chargebacks and other allowances at june 30, 2022 and december 31, 2021, respectively																150,410,000
accounts receivable, net of 113,970 and 105,260 of adjustments for chargebacks and other allowances at march 31, 2022 and december 31, 2021, respectively																	131,625,000
deferred revenue																	116,000	87,000	62,000	62,000	62,000	80,000	112,000	125,000	318,000	451,000	496,000	558,000	624,000	711,000	735,000																20,000	13,000	38,000	47,000	46,712	46,712																					4,545	9,091	18,182	27,273	34,091	68,182	102,273	136,363	136,363	136,363	136,363
accounts receivable, net of 105,260 and 100,328 of adjustments for chargebacks and other allowances at december 31, 2021 and december 31, 2020, respectively																		128,526,000
current income taxes payable																					3,659,000	3,906,000		8,286,000	15,223,000				3,453,000	5,022,000	318,000						3,656,000	2,398,000							481,000	4,253,000
accumulated other comprehensive loss, net of tax																		-3,055,000	-4,235,000	-5,433,000	-5,032,000	-11,437,000	-13,110,000	-14,049,000	-11,689,000	-4,871,000	-6,037,000	-5,013,000	-2,199,000	-379,000
accounts receivable, net of 108,456 and 100,328 of adjustments for chargebacks and other allowances at september 30, 2021 and december 31, 2020, respectively																			106,714,000
accounts receivable, net of 92,130 and 100,328 of adjustments for chargebacks and other allowances at june 30, 2021 and december 31, 2020, respectively																				92,648,000
accounts receivable, net of 80,722 and 100,328 of adjustments for chargebacks and other allowances at march 31, 2021 and december 31, 2020, respectively																					91,876,000
accounts receivable, net of 100,328 and 59,946 of adjustments for chargebacks and other allowances at december 31, 2020 and 2019, respectively																						95,793,000
(accumulated deficit)/retained earnings																						-4,972,000	-1,337,000	-1,771,000
accounts receivable, net of 86,418 and 59,946 of adjustments for chargebacks and other allowances at september 30, 2020 and 2019, respectively																							83,745,000
accounts receivable, net of 72,469 and 59,946 of adjustments for chargebacks and other allowances at june 30, 2020 and 2019, respectively																								73,162,000
accounts receivable, net of 104,711 and 59,946 of adjustments for chargebacks and other allowances at march 31, 2020 and december 31, 2019, respectively																									82,379,000
liabilities and stockholders' equity
stockholders' equity
total stockholders' equity																									201,171,000	212,791,000	213,130,000	207,656,000	199,712,000	197,263,000	192,465,000	185,110,000	179,644,000	174,756,000	182,801,000	176,546,000	172,212,000	169,648,000	168,830,000	163,776,000	160,178,000	160,082,000	155,893,000	149,500,000	144,740,000	139,785,000	99,492,000	91,595,000	92,092,000
total liabilities and stockholders' equity																									482,232,000	456,789,000	456,775,000	446,906,000	434,390,000	430,604,000	439,443,000	424,177,000	418,019,000	412,138,000	370,469,000	359,219,000	357,138,000	322,864,000	319,379,000	307,999,000	291,588,000	285,265,000	283,276,000	270,121,000	265,985,000	263,709,000	107,637,000	95,423,000	96,652,000
accounts receivable, net of 59,946 and 47,705 of adjustments for chargebacks and other allowances at december 31, 2019 and 2018, respectively																										72,129,000
current component of term loan and delayed draw term loan, net of deferred financing costs																										9,941,000
convertible notes, net of discount and deferred financing costs																											117,586,000	115,858,000	114,150,000	112,463,000	134,122,000	132,127,000	130,156,000	128,208,000	126,284,000	124,381,000	122,501,000	120,643,000	118,808,000	116,993,000	115,199,000	113,427,000
term loan and delayed draw term loan, net of deferred financing costs and current component																										175,808,000
accounts receivable, net of 47,687 and 47,705 of adjustments for chargebacks and other allowances at september 30, 2019 and december 31, 2018, respectively																											70,700,000
current component of term loan, net of deferred financing costs																											4,154,000	4,149,000
term loan, net of deferred financing costs and current component																											64,873,000	65,688,000
accounts receivable, net of 46,301 and 47,705 of adjustments for chargebacks and other allowances at june 30, 2019 and december 31, 2018, respectively																												76,274,000
accounts receivable, net of 48,849 and 47,705 of adjustments for chargebacks and other allowances at march 31, 2019 and december 31, 2018, respectively																													67,410,000
current component of non-current borrowing, net of deferred financing costs																													3,243,000
non-current borrowing, net of deferred financing costs and current borrowing component																													66,501,000
accounts receivable, net of 47,705 and 34,686 of adjustments for chargebacks and other allowances at december 31, 2018 and 2017, respectively																														64,842,000
other long-term assets																														1,468,000	1,412,000	1,049,000	823,000	829,000
current component of long-term borrowing, net of deferred financing costs																														3,256,000	5,692,000	5,217,000	3,805,000	3,353,000
long-term liabilities
long-term borrowing, net of deferred financing costs and current borrowing component																														67,296,000	65,954,000	67,262,000	68,569,000	69,946,000
other long-term liabilities																														496,000
retained earnings/																														11,488,000	6,058,000	1,021,000			5,623,000	903,000
accounts receivable, net of 50,603 and 34,686 of adjustments for chargebacks and other allowances at september 30, 2018 and december 31, 2017, respectively																															67,647,000
accounts receivable, net of 58,439 and 34,686 of adjustments for chargebacks and other allowances at june 30, 2018 and december 31, 2017, respectively																																56,115,000
accounts receivable, net of 30,786 and 34,686 of adjustments for chargebacks
and other allowances at march 31, 2018 and december 31, 2017, respectively																																	54,801,000
deferred tax asset, net of valuation allowance																																	23,163,000	22,667,000	30,829,000	27,933,000	26,962,000	26,227,000	18,400,000	17,751,000	17,397,000	17,316,000		7,027,000	7,369,000	7,796,000
accounts receivable, net of 34,686 and 31,535 of adjustments for chargebacks and other allowances at december 31, 2017 and 2016, respectively																																		58,788,000
long-term royalties																																						625,000	1,250,000	2,500,000
accounts receivable, net of 32,463 and 31,535 of adjustments for chargebacks and other allowances at september 30, 2017 and december 31, 2016, respectively																																			62,174,000
borrowings on line of credit																																			25,000,000	30,000,000
accounts receivable, net of 39,050 and 31,535 of adjustments for chargebacks and other allowances at june 30, 2017 and december 31, 2016, respectively																																				55,513,000
accounts receivable, net of 29,481 and 31,535 of adjustments for chargebacks and other allowances at march 31, 2017 and december 31, 2016, respectively																																					46,697,000
line of credit																																					30,000,000
accounts receivable, net of 31,535 and 13,586 of adjustments for chargebacks and other allowances at december 31, 2016 and 2015, respectively																																						45,895,000
accounts receivable, net of 22,385 and 13,586 of adjustments for chargebacks and other allowances at september 30, 2016 and december 31, 2015, respectively																																							47,477,000
accrued medicaid rebates																																							6,451,000	6,509,000	3,424,000	4,631,000	4,428,000	1,891,000	2,077,000	2,264,000
accounts receivable, net of 23,406 and 13,586 of adjustments for chargebacks and other allowances at june 30, 2016 and december 31, 2015, respectively																																								35,562,000
accounts receivable, net of 13,630 and 13,586 of adjustments for chargebacks and other allowances at march 31, 2016 and december 31, 2015, respectively																																									22,481,000
accounts receivable, net of 13,586 and 8,708 of adjustments for chargebacks and other allowances at december 31, 2015 and 2014, respectively																																										21,932,000
accounts receivable, net of 9,980 and 8,708 of adjustments for chargebacks and other allowances at september 30, 2015 and december 31, 2014, respectively																																											21,645,000
deferred tax assets, net of valuation allowance																																											8,266,000	7,999,000	7,776,000	7,643,000
deferred financing costs																																											2,674,000	2,885,000	3,096,000	3,307,000
convertible notes, net of discount																																											115,193,000	113,672,000	112,172,000	110,691,000
accounts receivable, net of 7,724 and 8,708 of adjustments for chargebacks and other allowances at june 30, 2015 and december 31, 2014, respectively																																												18,880,000
accounts receivable, net of 8,096 and 8,708 of adjustments for chargebacks and other allowances at march 31, 2015 and december 31, 2014, respectively																																													17,371,000
accounts receivable, net of 8,708 and 5,104 of adjustments for chargebacks and other allowances at december 31, 2014 and 2013, respectively																																														17,297,000
accounts receivable, net of 8,100 and 5,104 of allowances for chargebacks and other allowances at september 30, 2014 and december 31, 2013, respectively																																															14,570,000
prepaid expenses																																															599,000	493,000	566,000	580,000	580,597	251,765															1,011,099	836,505
property, plant, and equipment																																															5,046,000	4,625,000	4,518,000
accrued expenses																																															3,888,000	1,133,000	1,013,000	1,326,000	1,338,215	1,039,393
accounts receivable, net of 7,694 and 5,104 of allowances for chargebacks and other allowances at june 30, 2014 and december 31, 2013, respectively																																																7,794,000
accounts receivable, net of 4,874 and 5,104 of allowances for chargebacks and other allowances at march 31, 2014 and december 31, 2013, respectively																																																	10,907,000
accounts receivable, net of 5,104 and 6,124 of adjustments for chargebacks and other allowances at december 31, 2013 and 2012, respectively																																																		12,513,000
deferred loan costs
liabilities and stockholders' equity/
borrowings under line of credit
redeemable convertible preferred stock
stockholders' equity/
total stockholders' equity/																																																		40,962,000	36,688,805	35,494,810
total liabilities and stockholders' equity/																																																		44,500,000	43,285,828	41,658,023
land																																																			86,949	86,949
buildings																																																			3,682,006	3,682,006
machinery, furniture and equipment																																																			3,736,484	3,724,427
construction in progress																																																			197,948	176,276
property and equipment - sum																																																			7,703,387	7,669,658
less: accumulated depreciation																																																			3,062,900	2,928,928
total property and equipment																																																			4,640,487	4,740,730
other assets
total other assets																																																			12,550,582	12,798,309
accrued compensation																																																			2,535,746	2,726,167	879,385	1,078,683	463,942	1,031,624	767,672	1,597,329	1,476,036	1,072,972	743,643	526,022	1,156,638	887,817	602,346	529,066	759,245	285,084	241,488	290,583	878,555	712,626	511,324	717,409	569,831	391,913	289,604	368,522	361,570	324,813	223,579	492,980	610,195	493,448
current liabilities, discontinued operation																																																			131,613	366,390
10% convertible preferred stock, series a, 0.10 par value, stated value of 100
per share; no shares authorized, issued, or outstanding at september 30, 2013;
108,494 shares authorized, 102,774 shares issued and outstanding including cumulative dividends of 2,186,326 at december 31, 2012
10% convertible preferred stock, series b, 0.10 par value, stated value of 110
118,915 shares authorized, 78,491 shares issued and outstanding including cumulative dividends of 1,836,734 at december 31, 2012
12% convertible preferred stock, series c, 0.10 par value, stated value of 110
37,956 shares authorized, 34,810 shares issued and outstanding including cumulative dividends 994,471 at december 31, 2012
10% convertible preferred stock, series d, 0.10 par value, stated value of 30
3,400,000 shares authorized, 2,375,312 shares issued and outstanding including cumulative dividends of 4,184,858 at december 31, 2012
total redeemable convertible preferred stock
shares issued and 9,480,206 shares outstanding at september 30, 2013; 4,070,373 shares issued and outstanding at december 31, 2012																																																			954
shares issued and outstanding at september 30, 2013 and december 31, 2012
10% convertible preferred stock, series a, 0.10 par value, stated value of 100 per share; no shares authorized, issued, or outstanding at june 30, 2013; 108,494 shares authorized, 102,774 shares issued and outstanding including cumulative dividends of 2,186,326 at december 31, 2012
10% convertible preferred stock, series b, 0.10 par value, stated value of 110 per share; no shares authorized, issued, or outstanding at june 30, 2013; 118,915 shares authorized, 78,491 shares issued and outstanding including cumulative dividends of 1,836,734 at december 31, 2012
12% convertible preferred stock, series c, 0.10 par value, stated value of 110 per share; no shares authorized, issued, or outstanding at june 30, 2013; 37,956 shares authorized, 34,810 shares issued and outstanding including cumulative dividends 994,471 at december 31, 2012
10% convertible preferred stock, series d, 0.10 par value, stated value of 30 per share; no shares authorized, issued, or outstanding at june 30, 2013; 3,400,000 shares authorized, 2,375,312 shares issued and outstanding including cumulative dividends of 4,184,858 at december 31, 2012
prepaid expenses and other assets																																																					277,874	378,803	534,037	512,640	716,920	801,147	943,710	1,013,315	1,137,540	2,469,879	1,150,798	883,188	1,156,514	1,487,160			1,133,012	1,070,051	998,210	677,330	336,156	337,420
current assets - sum																																																					31,926,746	35,173,144	38,583,132	42,929,685	50,190,652	58,026,381	70,543,909	38,139,321	52,486,561	40,625,130	36,676,815	47,318,456	42,452,263	31,410,270	14,218,628	7,733,059	11,652,109	16,087,080	18,551,812	23,454,040	27,944,547	31,006,910	33,346,262	35,071,415	18,918,939	22,208,474	10,540,224	4,712,909	7,282,763	9,346,996	10,565,289	12,250,938
investments																																																					3,413,762	3,413,762	3,413,762	3,413,762	3,413,762	3,405,807	3,405,807	3,405,807	3,405,807	3,405,807	3,340,000	3,626,000	3,626,000	3,626,000
deposits																																																					15,878	15,878	30,088	88,793	86,203	86,203	86,203	86,203	99,937	99,937	99,937	154,937	527,463	652,679	879,956	903,442	637,397	637,397	600,797	573,097	573,097	39,536
other accrued expenses																																																					112,784	502,452	860,094	1,028,623	2,035,576	2,479,697	2,747,791	2,872,081	2,235,633	1,681,956	1,415,693	1,082,976	1,608,223	942,922	480,909	865,011	428,905	374,887	266,979	283,849	102,750	77,712	68,500	128,500	175,236	65,500	192,651	282,713	104,794	147,125	239,834	274,753
current portion of convertible senior notes																																																					8,169,215	7,883,886	7,593,216	10,477,635			1,234,000	1,187,497	1,149,820	1,111,132
capital stock
issued and outstanding
2013 - 65,211; 2012 - 65,211 class c special stock																																																					391
2013 - 24,422,240; 2012 - 24,422,240 common stock																																																					273,277,795
issued and outstanding - sum																																																					273,278,186	273,132,392	273,259,236	265,768,782	265,500,001	255,054,440	254,739,100	209,387,067	209,017,188	184,777,766	167,662,697	167,394,808	152,980,536	135,264,822	98,130,289	86,390,922	86,068,355	85,733,079	85,565,418	84,864,443	84,500,713	84,206,974	83,987,921	83,659,086	65,331,737	64,968,278	64,915,872		57,668,430	56,653,617	56,653,617	56,653,618
current liabilities - sum																																																						10,593,665	10,922,066	16,373,638	6,084,953	7,227,703	11,499,718	11,481,498	12,632,886	8,183,327	7,095,131	6,690,250	6,225,015	3,930,117	4,777,228	3,716,522	3,104,726	3,852,952	4,570,263	3,621,362	2,926,799	1,515,850										1,550,696
long-term convertible senior notes																																																									10,493,589	17,336,760	19,242,333	19,751,836	18,036,513	17,436,201
2012 - 65,211; 2011 - 65,214 class c special stock																																																						391	65	65
2012 - 24,422,240; 2011 - 18,269,754 common stock																																																						273,132,001
2012 - 24,422,240; 2011 - 18,269,755 common stock																																																							273,259,171
2012 - 20,137,526 ; 2011 - 18,269,755 common stock																																																								265,768,717
2012 - 391,286; 2011 - 391,286 class c special stock																																																									391
2012 - 120,826,861; 2011 - 109,618,529 common stock																																																									265,499,610
2011 - 391,286; 2010 - 391,286 class c special stock																																																										391	391	391	391
2011 - 109,618,529; 2010 - 81,391,130 common stock																																																										255,054,049	254,738,709
2011 - 93,600,446; 2010 - 81,391,130 common stock																																																												209,386,676
2011 - 93,590,612; 2010 - 81,391,130 common stock																																																													209,016,797
2010 - 391,286; 2009 - 391,286 class c special stock																																																														391	391	391	391
2010 - 81,391,130; 2009 - 53,262,568 common stock																																																														184,777,375
due to licensor - antares																																																																	11,889		7,871	16,200	4,887	5,393	4,663	4,972	6,932		881,328	898,818	875,000	2,625,000
convertible senior notes due 2011 and 2013																																																															18,364,333	18,467,333	18,085,417	16,676,417
2010 - 70,802,894; 2009 - 53,262,568 common stock																																																															167,662,306	167,394,417
2010 - 63,667,194; 2009 - 53,262,568 common stock																																																																	152,980,145
short-term investments																																																																						3,026,334	11,770,374	12,429,841	14,472,050	15,005,976	3,952,633	3,903,529	3,856,965	3,795,977	9,903,757	4,371,626	6,984,609	8,790,888	10,045,355	11,692,960
due to licensor — antares																																																																		18,033								1,063
2009 — 391,286; 2008 — 391,286 class c special stock																																																																		391
2009 — 53,262,568; 2008 — 27,042,764 common stock																																																																		135,264,431
investment in matc																																																																			140,000	140,000	140,000	140,000	140,000	140,000	140,000	140,000
2009 - 391,286; 2008 - 391,286 class c special stock																																																																			391	391	391
2009 - 33,042,764; 2008 - 27,042,764 common stock																																																																			98,129,898
deferred acquisition costs																																																																				793,398
2009 - 27,042,764; 2008 - 27,042,764 common stock																																																																				86,390,531	86,067,964
2008 - 391,286; 2007 - 391,286 class c special stock																																																																						391	391	391	391
2008 - 27,042,764; 2007 - 26,794,607 common stock																																																																						85,732,688	85,565,027
accumulated other comprehensive income																																																																							427,500
2008 - 26,881,950; 2007 - 26,794,607 common stock																																																																								84,864,052
see accompanying notes to the condensed financial statements.
2008 - 26,794,607; 2007 - 26,794,607 common stock																																																																									84,500,322
accumulated other comprehensive loss																																																																									-602,000
provision for contingencies																																																																													412,941	550,588				750,000
2007-391,286; 2006-391,286 class c special stock																																																																										391
2007-26,794,607; 2006-22,975,040 common stock																																																																										84,206,583
prepaid expenses and other sundry assets																																																																											391,301	208,379	256,521	248,116	270,293	207,678	227,965	245,465	265,792	178,455
security deposits																																																																											25,326	25,326	25,326	25,326	25,325	25,325	11,992	11,992
accrual for contingencies																																																																											137,647	275,294			688,234	890,000	890,000
2007 - 391,286; 2006 - 391,286 class c special stock																																																																											391	391	391
2007 - 26,787,273; 2006 - 22,975,040 common stock																																																																											83,987,530
see accompanying notes to the financial statements.
2007 - 26,743,349; 2006 - 22,975,040 common stock																																																																												83,658,695
2007 - 23,027,540; 2006 - 22,975,040 common stock																																																																													65,331,346
long term liabilities
leasehold retirement liability																																																																															43,000	21,500	21,500	21,500
total long term liabilities																																																																															43,000	21,500	55,591	89,682
2006 - 391,286; 2005 - 391,286 class c special stock																																																																														391	398	398	398
2006 - 22,975,040; 2005 - 19,007,800 common stock																																																																														64,967,887	64,915,474
deferred unearned compensation
deficit accumulated during the development stage																																																																															-55,886,776
capital stock issued and outstanding
2006 - 19,160,694; 2005 - 19,007,800 common stock																																																																																57,719,334	57,668,032
capital stock issued and outstanding - sum																																																																																57,719,732
due to antares
2005 - 391,286; 2004 - 391,286 class c special stock																																																																																		398
2005 - 19,007,800; 2004 - 18,955,181 common stock																																																																																		56,653,219
deferred revenue - long term																																																																																			102,273
commitments
391,286 (2004 - 391,286) class c special stock																																																																																			398	398
19,007,800 (2004 - 18,955,181) common stock																																																																																			56,653,219	56,653,220

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31

cash flows from operating activities
net income	29,492,000	27,490,000	26,617,000	8,549,000	15,681,000	-10,276,000	-24,166,000	-2,287,000	18,207,000	1,155,000	9,940,000	6,245,000	1,439,000				-20,130,000				86,000	-3,635,000	434,000	-12,336,000	-7,011,000	-4,835,000	3,895,000	6,585,000	449,000	5,430,000	5,037,000	2,777,000	2,250,000	-9,629,000	4,720,000	2,681,000	1,152,000	-1,080,000	2,543,000	1,125,000	1,346,000	2,876,000	4,559,000	3,571,000	4,369,000	21,005,000	6,746,000	-2,363,000	3,359,000
adjustments to reconcile net income to net cash and cash equivalents from operating activities:
stock-based compensation	10,191,000	9,768,000	9,691,000	9,602,000	8,868,000	7,061,000	7,485,000	7,864,000	6,934,000	5,621,000	5,444,000	5,249,000	4,338,000	3,737,000	3,869,000	3,756,000	3,237,000	2,968,000	2,808,000	2,844,000	1,869,000	2,393,000	2,383,000	5,736,000	2,424,000	2,444,000	2,470,000	2,593,000	1,710,000	1,828,000	1,795,000	1,782,000	1,377,000	1,422,000	1,475,000	1,807,000	1,386,000	1,380,000	1,365,000	2,217,000	1,105,000	1,139,000	1,120,000	1,029,000	568,000	704,000	693,000	1,979,000	47,000	33,049
deferred taxes	2,515,000	2,356,000	18,800,000	-3,536,000	-3,383,000	-17,530,000	-5,588,000	-1,899,000	3,104,000	-8,346,000	-3,257,000	-910,000	773,000	-1,625,000	-2,250,000	-3,914,000	-7,464,000	-8,089,000	-1,989,000	-6,397,000	-279,000	-4,173,000	5,068,000	5,143,000	-19,243,000	-2,701,000	-3,728,000	-2,540,000	-165,000	-2,599,000	-1,594,000	-491,000	-496,000	8,162,000	-2,896,000	-971,000	-735,000	-7,827,000	-649,000	-354,000	-81,000	-1,932,000	-358,000	119,000	294,000
depreciation and amortization	20,919,000	22,613,000	22,632,000	23,281,000	22,891,000	22,600,000	15,748,000	14,697,000	14,686,000	15,194,000	15,207,000	14,690,000	14,700,000	15,572,000	15,350,000	14,174,000	14,557,000	13,684,000	11,346,000	11,324,000	10,898,000	10,899,000	11,358,000	11,198,000	11,183,000	9,564,000	9,473,000	9,472,000	16,103,000	8,686,000	8,548,000	8,313,000	8,195,000	7,022,000	7,099,000	7,101,000	6,706,000	5,812,000	5,966,000	5,956,000	4,609,000	2,111,000	2,047,000	1,415,000	1,327,000	1,282,000	1,187,000	706,000	703,000	437,172	381,699	124,743	166,386	171,398	25,749	30,933	30,866	30,108	35,669	40,519	41,944	39,019	41,000	42,546	45,421	41,393	33,308	33,333	29,246	9,296	11,759	12,309	9,773	10,315	17,993	28,600	32,916	32,490	30,725	27,109	27,457	24,489
unrealized loss on investment in equity securities	-5,753,000			-332,000	921,000
non-cash operating lease expense	453,000	555,000	358,000	394,000	452,000	392,000	384,000	377,000	373,000	381,000	827,000
non-cash interest	358,000	351,000	340,000	341,000	324,000	323,000	121,000	96,000	102,000	952,000	997,000	986,000	987,000	998,000	994,000	987,000	982,000	794,000	577,000	569,000	572,000	588,000
contingent consideration fair value adjustment	-182,000	-5,727,000	-14,470,000	1,277,000	-12,092,000	-1,893,000	825,000	359,000	90,000	1,985,000	-2,555,000	1,035,000	961,000	1,924,000	2,476,000	-1,095,000	753,000
changes in operating assets and liabilities:
accounts receivable	25,528,000	-27,856,000	-26,965,000	-5,491,000	1,782,000	-25,513,000	8,438,000	6,327,000	-10,339,000	16,763,000	-5,918,000	1,789,000	-9,275,000	-25,005,000	9,977,000	-18,785,000	-3,099,000	5,373,000	-14,066,000	-772,000	3,917,000	-12,048,000	-10,583,000	9,217,000	-10,250,000	-1,429,000	5,574,000	-8,864,000	-2,568,000	2,805,000	-10,221,000	-1,314,000	3,987,000	3,386,000	-6,661,000	-8,816,000	-802,000	1,582,000	-11,915,000	-13,081,000	-549,000	-287,000	-2,765,000	-1,509,000	-74,000	-2,727,000	-6,776,000	3,113,000	1,606,000	-2,998,305	-3,087,590											0	53,156			94,334	79,062					8,926	-15,652	3,567,726	-4,953	-62,628	6,995,818
inventories	-437,000	3,732,000	-8,160,000	-908,000	-625,000	-675,000	-6,360,000	-11,611,000	-2,641,000	-4,605,000	-2,268,000	-669,000	1,701,000	-9,462,000	-3,312,000	-9,390,000	-1,462,000	-5,549,000	5,950,000	1,947,000	876,000	-1,608,000	-5,206,000	362,000	3,693,000	-1,989,000	-878,000	-3,264,000	-1,529,000	-497,000	-53,000	-3,262,000	3,433,000	751,000	3,829,000	3,586,000	-2,810,000	2,078,000	-3,209,000	-272,000	-535,000	354,000	-1,040,000	-1,964,000	-3,219,000	-172,000	-902,000	-822,000	-1,572,000	-708,525	-224,474
prepaid expenses and other assets	2,687,000	-4,460,000	-6,454,000	9,835,000	-3,945,000	-1,693,000	2,045,000																																														100,928				84,227				1,332,339				455,862							-341,174	-532,297
accounts payable	5,358,000	-7,235,000	13,766,000	3,076,000	5,549,000	-6,821,000	-3,079,000	-1,147,000	11,526,000	2,780,000	5,572,000	-3,905,000	3,105,000	10,065,000	-9,074,000	5,056,000	-1,009,000	9,770,000	-1,292,000	-774,000	2,462,000	-2,148,000	-811,000	1,997,000	-1,332,000	2,909,000	798,000	-673,000	2,005,000	1,216,000	-2,321,000	2,866,000	1,705,000	-2,075,000	2,423,000	-1,663,000	1,318,000	-1,486,000	-288,000	1,961,000	889,000	-897,000	1,249,000	-908,000	-471,000	-405,000	328,000	-929,000	1,231,000	-658,280	452,059
accrued royalties	-14,655,000	-2,750,000	15,217,000	12,317,000	1,087,000	-821,000	3,090,000	4,882,000	-801,000	9,637,000	-2,091,000	-227,000	-350,000	2,722,000	290,000	1,297,000	-1,227,000	2,144,000	-692,000	-622,000	-1,097,000	319,000	84,000	-281,000	1,201,000	-443,000	-738,000	825,000	-3,016,000	1,001,000	-764,000	-3,142,000	-803,000	423,000	-139,000	1,549,000	-2,250,000	187,000	3,659,000
income taxes	14,087,000	472,000	-12,548,000
accrued government rebates	-4,737,000	6,123,000	4,166,000	10,222,000	3,930,000	7,635,000	-1,631,000	2,814,000	-2,658,000	1,347,000	1,048,000	1,166,000	-2,265,000	2,127,000	-695,000	4,883,000	-935,000	-6,965,000	2,973,000	68,000	846,000	-3,852,000	1,961,000	1,687,000	-871,000	-283,000	-1,759,000	2,391,000	-422,000	-40,000	3,758,000	-1,215,000	-1,459,000	2,175,000	2,221,000	-1,121,000	-1,236,000
returned goods reserve	-6,451,000	-502,000	1,322,000	6,220,000	3,189,000	4,806,000	77,000	1,045,000	3,174,000	-1,761,000	1,640,000	-4,314,000	713,000	-581,000	-915,000	-655,000	-248,000	1,412,000	337,000	2,962,000	1,792,000	3,913,000	3,048,000	2,389,000	1,019,000	650,000	1,289,000	1,097,000	1,007,000	1,712,000	1,076,000	744,000	746,000	-43,000	759,000	1,782,000	20,000
accrued expenses, accrued compensation, and other	-20,998,000	5,623,000	1,821,000	11,859,000	-17,077,000	5,446,000	8,985,000	7,030,000	-13,077,000	4,451,000	4,981,000	-153,000	2,992,000	2,835,000	-4,926,000	5,631,000	-4,445,000	-4,170,000	-6,471,000	8,409,000	-1,406,000	278,000	111,000	2,332,000	-365,000	-826,000	2,241,000	-1,046,000	55,000
net cash and cash equivalents from operating activities	58,375,000	30,367,000	44,055,000	75,812,000	34,991,000	15,860,000	12,474,000	17,414,000	18,269,000	44,740,000	32,169,000	20,626,000	21,424,000	-4,400,000	3,623,000	-11,484,000	-18,942,000	-12,185,000	-5,402,000	241,000	20,668,000	-5,709,000	-1,614,000	20,880,000	1,710,000	4,803,000	21,793,000	4,744,000	14,291,000	27,232,000	8,319,000	8,593,000	22,930,000	15,805,000	17,084,000	1,000	6,529,000	12,082,000	1,084,000	3,337,000	10,969,000	4,702,000	10,236,000	1,206,000	1,120,000	10,741,000	4,159,000	1,954,000	5,179,000	-2,864,620	-1,631,392
cash flows from investing activities
acquisition of product rights, intangible assets, and other related assets	-5,250,000	-159,000	-60,000	-2,895,000	-17,372,000	-86,000
acquisition of property and equipment	-6,074,000	-1,244,000	-6,103,000	-4,014,000	-2,474,000	-2,394,000	-4,812,000	-4,449,000	-4,581,000	-2,279,000	-1,739,000	-2,501,000	-2,349,000	-3,138,000	-2,468,000	-1,321,000	-1,949,000	-356,000	-571,000	-932,000	-698,000	-2,110,000	-1,761,000	-725,000	-1,539,000	-1,703,000	-1,523,000	-1,634,000	-1,775,000	-1,007,000	-1,372,000	-1,086,000	-2,278,000	-3,447,000	-2,480,000	-2,304,000	-2,138,000	-1,389,000	-1,089,000	-719,000	-1,369,000	-1,105,000	-768,000	-198,000	-112,000	-338,000	-411,000	-253,000	-118,000
net cash and cash equivalents from investing activities	-11,324,000	-1,403,000	-6,163,000	-6,909,000	-19,846,000	-10,681,000	-398,522,000	-4,449,000	8,933,000	-4,779,000	-4,553,000	-6,826,000	-2,353,000	-3,142,000	-9,814,000	-604,000	-2,178,000	-82,213,000	-583,000	-21,950,000	-737,000	-2,119,000	-5,809,000	-2,848,000	-57,546,000	-1,374,000	-1,932,000	-3,958,000	-20,285,000	-407,000	-18,439,000	-6,255,000	-2,278,000	-50,115,000	-2,480,000	-2,304,000	-53,094,000	-1,390,000	-1,089,000	-66,032,000	-85,551,000	-1,105,000	-26,768,000	-198,000	-4,612,000	-338,000	-22,528,000	-253,000	-12,635,000	2,230,973	-33,729
cash flows from financing activities
principal payments on borrowings	-4,063,000	-4,063,000	-2,031,000
series a convertible preferred stock dividends paid		0	-344,000	-407,000	-406,000	-406,000	-406,000	-407,000	-406,000	-406,000	-406,000	-407,000	-406,000	-407,000	-406,000	-407,000	-405,000
proceeds from stock option exercises and espp purchases	2,202,000	38,000	9,790,000	1,242,000	2,534,000	1,700,000	1,192,000	1,005,000	2,591,000	1,969,000	5,581,000	1,289,000	157,000	768,000	484,000	203,000	3,000	1,733,000	0			169,000	0
treasury stock purchases for restricted stock vests	-19,755,000	-611,000	-1,044,000	-551,000	-10,003,000	-318,000	-680,000	-1,300,000	-8,661,000	-231,000	-670,000	-537,000	-3,549,000	-119,000	-239,000	-483,000	-1,118,000	-1,000	-73,000	-468,000	-348,000	0	0	-1,035,000	-488,000
net cash and cash equivalents from financing activities	-21,616,000	-4,636,000	6,345,000	-1,747,000	-9,906,000	-4,907,000	291,030,000	-1,452,000	-19,726,000	-11,918,000	3,755,000	80,150,000	-4,548,000	-508,000	-911,000				-3,022,000	20,898,000	-2,725,000	-2,208,000	-2,378,000	-10,744,000	13,891,000		-770,000	1,580,000	1,206,000		-731,000	691,000	170,000	47,425,000	-4,940,000	-153,000	30,025,000	518,000	1,146,000	-38,000	-2,355,000	174,000	714,000	160,000	18,000	123,584,000	458,000	-113,000	47,724,000	808,869	0
effect of exchange rate changes on cash, cash equivalents and restricted cash	156,000	-1,353,000	576,000	841,000	-297,000	-395,000
net change in cash, cash equivalents, and restricted cash	25,591,000	22,975,000	44,813,000	67,997,000	4,942,000	-123,000	-95,093,000	11,513,000	7,476,000		31,371,000	93,950,000	14,523,000
cash, cash equivalents, and restricted cash, beginning of period	285,621,000		0	0	144,894,000		0	0	221,121,000		0	0	53,234,000	0	0	0	105,301,000	0	0	0	12,867,000	0	0	0	67,361,000	0	0	0	48,029,000	0	0	0	36,150,000	0	0	0	32,367,000
cash, cash equivalents, and restricted cash end of period	311,212,000		44,813,000	67,997,000	149,836,000
reconciliation of cash, cash equivalents, and restricted cash, beginning of period
cash and cash equivalents	285,585,000							0	221,121,000		0	0	48,228,000	0	0	0	100,300,000	0	0	0	7,864,000	0	0	0	62,332,000		0	0	43,008,000	0	0	0	31,144,000	0	0	0	27,365,000
restricted cash	36,000										0	0	5,006,000	0	0	0	5,001,000	0	0	0	5,003,000	0	0	0	5,029,000	0	0	0	5,021,000	0	0	0	5,006,000	0	0	0	5,002,000
reconciliation of cash, cash equivalents, and restricted cash, end of period
cash, cash equivalents, and restricted cash, end of period	311,212,000										31,371,000	93,950,000	67,757,000	-8,050,000	-7,102,000	-13,525,000	81,911,000	85,046,000	-9,007,000	-811,000	30,073,000	-10,036,000	-9,801,000	7,288,000	25,416,000	2,663,000	19,091,000	2,366,000	43,241,000	-1,121,000	-10,851,000	3,029,000	56,972,000	13,115,000	9,664,000	-2,456,000	15,827,000
supplemental disclosure for cash flow information:
cash paid for interest, net of amounts capitalized	7,824,000			4,966,000	8,895,000			8,209,000	7,946,000				4,293,000	7,449,000	2,628,000	5,763,000	5,637,000	3,783,000	1,969,000	1,970,000	1,983,000	1,851,000	1,539,000	1,693,000	1,848,000	2,465,000	690,000	2,488,000	449,000	2,522,000	584,000	2,726,000	453,000	1,562,000	100,000
cash paid for income taxes, net of refunds received	-6,065,000
supplemental non-cash investing and financing activities:
accrued consideration for acquired product rights and intangible assets	1,085,000
property and equipment purchased and included in accounts payable	784,000			-734,000	1,022,000			396,000	1,222,000				729,000	248,000	-575,000	526,000	253,000	124,000	-91,000	-99,000	218,000	-51,000	62,000	23,000	138,000	244,000	346,000	-37,000	170,000	411,000	-123,000	197,000	36,000	131,000	245,000	31,000	78,000	145,000	57,000	-40,000	85,000
unrealized gain on investment in equity securities		-273,000				1,991,000	-1,355,000	2,712,000	-9,655,000
loss on disposal of assets		87,000
loss on extinguishment of debt
amortization of inventory step up						10,375,000
asset impairment charges		0												0	-1,000
changes in operating assets and liabilities, net of acquisitions:
acquisition of alimera, net of cash acquired						-8,201,000
proceeds from the sale of building						0	0	0	13,514,000
proceeds from convertible notes						0
proceeds from term loan						0
purchase of capped call transaction						0
proceeds from public offering
payments on contingent consideration		0				0	0	0	-12,500,000
debt issuance costs						-1,977,000
repayment on borrowings under credit agreement						0
payment of accrued licensor payment
cash and cash equivalents, beginning of year
cash, cash equivalents and restricted cash, end of year
loss on debt extinguishment
payment of accrued licensor payments
gain on sale of building						0	0	0	-5,347,000
cash paid for income taxes				16,188,000	285,000			16,352,000	852,000				2,741,000	132,000	32,000			2,011,000	0	8,248,000	112,000	106,000	4,355,000	428,000	95,000	140,000	1,170,000			2,507,000	995,000			5,293,000	2,611,000	9,878,000	4,000	3,690,000	3,641,000	563,000	1,643,000	2,587,000	1,218,000	3,421,000	6,029,000	10,000	77,000	0	60,000
income taxes payable					7,439,000
principal payments on borrowings under term loan a					-2,031,000
acquired in-process research and development														0								0	0	0	3,753,000					0	0
gain on sale of andas														0	0
acquisition of novitium pharma llc, net of cash acquired														0	0
proceeds from the sale of long-lived assets														0	0
principal payments on borrowings under credit agreements						-2,031,000
changes in operating assets and liabilities, net of acquisition:
prepaid income taxes							-3,237,000
cash. cash equivalents, and restricted cash end of period
payments on borrowings under credit agreements								-750,000	-750,000	-750,000	-750,000	-750,000	-750,000	-750,000	-750,000	-750,000	-750,000
cash and cash equivalents, end of period								11,513,000	228,597,000					-8,050,000	-7,102,000	-13,525,000	81,911,000	85,046,000	-9,007,000	-811,000	30,073,000	-10,036,000	-9,801,000															11,210,000	1,141,000	-62,733,000	77,747,000	3,771,000	-15,818,000	1,168,000	165,563,000	133,987,000	-17,911,000	1,588,000	51,373,000	175,194	-1,665,121
right-of-use assets obtained in exchange for lease obligations
prepaid expenses and other current assets									1,353,000	-8,379,000	-2,085,000	-64,000	1,513,000	-3,415,000	1,054,000	1,700,000	-137,000	-1,294,000	219,000	823,000	379,000	-2,503,000	-241,000	-150,000	1,028,000	913,000	-1,714,000	846,000	358,000	627,000	-2,875,000	576,000	530,000	1,348,000	-2,201,000	861,000	-25,000	-24,000	1,369,000	-2,193,000	201,000	-312,000	-370,000
current income taxes payable									3,238,000	7,565,000	4,687,000	-353,000	92,000	-49,000	-1,765,000	-31,000	1,685,000	-637,000	-655,000	-6,034,000	-247,000																								-3,772,000
changes in operating assets and liabilities, net of acquisition
acquisition of product rights, ipr&d, and other related assets												-4,325,000	-4,000	-4,000	-7,346,000	0	-229,000	-12,000	-12,000	-21,018,000	-39,000	-9,000	-4,048,000	-2,123,000	-56,007,000	329,000	-409,000			0	0
proceeds from public offering, net of transaction expenses										0
payments on term loan and delayed draw term loan agreements																		-2,828,000	-2,828,000	-2,829,000	-2,377,000	-2,377,000	-2,378,000
borrowings under prior revolver agreement
repayment of prior credit facility
borrowings under the credit facility, net of issuance costs
proceeds from issuance of convertible preferred stock
net change in cash and cash equivalents														-8,050,000	-7,102,000	-13,525,000	-23,390,000	85,046,000	-9,007,000	-811,000	17,206,000	-10,036,000	-9,801,000
cash and cash equivalents, end of year
net loss														-4,243,000	-8,600,000				-4,447,000																																		-2,290,649	-3,987,331	-6,121,815	-7,344,116	-10,264,477	-6,648,905	-12,733,692	-14,975,231	-17,250,676	-13,271,735	-11,589,711	-10,794,351	-10,540,419	-32,485,898	-6,370,557	-4,620,701	-4,050,612		-6,585,084	-6,048,067	-3,626,638		-1,693,044	-2,400,309	-1,817,018
adjustments to reconcile net loss to net cash and cash equivalents from operating activities:

payments on revolver agreement																						0	0
borrowings under the credit facility
proceeds from issuance of common stock in public offering
cash paid for costs of share issuances
payments of debt issuance costs																		-13,706,000	-121,000
cash and cash equivalents, beginning of period														0	0	0	105,301,000	0	0	0	12,867,000	0	0															0	0	0	154,684,000	0	0	0	169,037,000	0	0	0	11,105,000	-28	0
fair value of contingent consideration in a business combination
fair value of equity issued as consideration in a business combination
acquisition of product rights included in accounts payable														0
debt issuance costs in accrued expenses																				-34,000	115,000
net cash and cash equivalents from by financing activities																	-2,270,000
acquisition of product rights, ipr&d, and other related assets included in returned goods reserve and derivatives and other non-current liabilities																						-8,000
asset impairment charge																						341,000
borrowings under delayed draw term loan agreement
borrowings under revolver agreement																		0	0			0	0	0	15,000,000
convertible preferred stock dividends paid
repayment of convertible notes
acquisition of product rights, ipr&d, and other related assets included in returned goods reserve and accrued liabilities																					388,000
loss on repurchase of convertible notes
current income taxes																						5,527,000	-9,907,000	-6,937,000	16,299,000	-262,000	2,628,000	-6,895,000	-1,569,000	4,704,000	2,052,000	-1,672,000	1,100,000	890,000	1,939,000	-7,647,000	1,258,000	3,327,000	-779,000	1,000,000	-23,000	-155,000	50,000
acquisition of wellspring pharma services inc., net of cash acquired
payment of debt issuance and convertible debt repurchase costs
unwinding of portion of call option overlay
non-cash interest relating to convertible notes and loan cost amortization																								523,000	182,000	1,345,000	1,913,000	1,893,000	1,873,000	2,073,000	2,155,000	2,130,000	2,107,000	1,943,000	1,933,000	1,908,000	1,882,000	1,860,000	1,939,000	1,757,000	1,725,000	1,696,000	1,747,000	1,705,000	1,683,000
adjustments to reconcile net loss to net cash and cash equivalents provided by operating activities:
payments on term loan agreement																									-902,000	-902,000	-903,000	0	-902,000	-938,000	-937,000	0	-938,000
proceeds from stock option exercises																									281,000		133,000	2,303,000	2,416,000	161,000	206,000	1,100,000	1,511,000	162,000	60,000	106,000	25,000	208,000	858,000	360,000	144,000	161,000	414,000	235,000	9,000	42,000	34,000	0	743,000
change in cash, cash equivalents, and restricted cash																									-41,945,000		19,091,000	2,366,000	-4,788,000		-10,851,000	3,029,000	20,822,000		9,664,000	-2,456,000	-16,540,000
acquisition of product rights, ipr&d, and other related assets included in accounts payable or accrued expenses																									1,940,000
intangible asset impairment charge
borrowings under term loan agreement
treasury stock purchases for restricted stock vestings																										0	0	-723,000	-308,000	0	0	-409,000	-250,000
net cash and cash equivalents provided/(used in) by financing activities
reconciliation of cash, cash equivalents, and restricted cash, beginning of period cash and cash equivalents
reconciliation of cash, cash equivalents, and restricted cash, end of period cash and cash equivalents
acquisition of marketing and distribution rights included in accounts payable
acquired product rights and in-process research and development
payment of debt issuance costs																															0	0	-153,000					0	0
acquisition of product rights and other related assets																													-18,510,000					-46,668,000	0	0	-50,956,000	0	0	-60,312,000	-84,182,000	0	-26,000,000	0	-4,500,000	0
acquisiton of wellspring pharma services inc., net of cash acquired
excess tax benefit from share-based compensation awards																																						310,000	288,000	18,000	1,000	126,000	187,000	38,000	9,000	352,000	424,000	-99,000	107,000
repurchase of common stock under the stock repurchase program																																						0	0
repurchase of convertible notes
net cash and cash equivalents (used in)/provided by financing activities
accrued royalties related to asset purchase																																						0	0
accrued compensation and related expenses																															702,000	-85,000	-811,000	297,000	782,000	92,000	-496,000	205,000	355,000	349,000	-466,000	169,000	175,000	331,000	-835,000
accrued expenses and other																															1,024,000	-749,000	1,069,000	-1,170,000	1,801,000	-1,148,000	1,161,000
net borrowings under line of credit agreement																																			-5,000,000	0	30,000,000
adjustments to reconcile net income to net cash and cash equivalents provided by operating activities:
treasury stock purchases for restricted stock vestings and forfeitures																																			0			0	0
adjustments to reconcile net loss to net cash and cash equivalents
provided by operating activities:
changes in restricted cash																																						-1,000	0
net proceeds from equity offering																																														0	0	-14,000	46,694,000
net proceeds from convertible debt offering
purchase of call option overlay
proceeds from warrant exercise
change in cash and cash equivalents																																						11,210,000	1,141,000	-62,733,000	-76,937,000	3,771,000	-15,818,000	1,168,000	-3,474,000	133,987,000	-17,911,000	1,588,000	40,268,000	175,222	-1,665,121
accrued medicaid rebates																																							-58,000	3,085,000	-1,207,000	203,000	2,537,000	-186,000	-187,000
accrued expenses, returned goods reserve, and other																																							786,000	-636,000	3,955,000		1,245,000	-825,000	1,000,000
cash paid for interest																																							0			2,157,000	0							388	0												0
repurchase of common stock																																									-2,500,000
accrued royalties assumed in asset purchase																																									1,199,000
loss on disposal of property and equipment																																										0
non-cash compensation relating to business combination																																																		-524	0
changes in operating assets and liabilities, net of those acquired in business combination:
accrued expenses, returned goods reserve and other
net cash and cash equivalents from continuing operations																																														10,741,000				-2,758,436	-1,546,952
net cash from discontinued operation																																																		-106,184	-84,440
cash acquired in business combination																																																		558	0
release of restricted cash
repayment of line of credit
treasury stock purchases																																																		-438	0
issuance of common stock in connection with business combination
cancellation of series d, series c, series b, and series a preferred stock
acquired non-cash net assets
preferred stock dividends accrued
contingent payable for asset purchase
property and equipment purchased on credit																																											59,000	-55,000	105,000
prepaid expenses																																													437,000	-539,000	-106,000	73,000	14,000	143	-328,831
non-cash interest relating to equity-linked securities and loan cost amortization
accrued expenses, returned goods reserve and deferred revenue																																															2,989,000	197,000	-209,000	407,858	216,528
net cash and cash equivalents from discontinued operation
borrowings under line of credit
proceeds from warrant exercises																																															0	0	180,000
acquisition of intangible assets																																																0	-12,517,000
adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
accrued compensation
(repayments)/borrowings under line of credit																																																		307	0
issuance of common and preferred stock upon cashless warrant exercise
issuance of preferred stock upon convertible debt conversion
net loss from continuing operations																																																			1,040,706
used in operating activities:
non-cash interest relating to convertible debt and loan cost amortization																																																			0
acquisition of property and equipment, net of disposals																																																			-33,729
issuance of common stock in business combination																																																			0
cancellation of series d, series c, series b, series a, and common stock
acquired intangibles																																																			0
acquired goodwill																																																			0
acquired restricted cash																																																			0
other acquired tangible assets																																																			0
assumed liabilities																																																			0
preferred stock dividends																																																			0
exchange of series d, series c, series b, series a, and common stock
adjustments to reconcile net loss to net cash (used in) operating activities
loss on disposal of fixed assets																																																							117,362	0	432			0	2,099
gain on sale of intellectual property
employee and director stock-based compensation																																																					145,794				313,027				300,385
convertible note fair value adjustment																																																					285,329	290,671	843,412	-15,953	3,210,338	-1,905,573	-463,000	1,753,000	639,000
changes in other assets and liabilities affecting cash flows from operations
accounts payable and accrued liabilities																																																										-2,858,956	-190,360	-1,227,452	4,410,871	-40,967	404,879	477,124	2,301,042	-1,675,443				-615,621	694,770	701,068	1,409,626	2,051,657	-228,943	324,297	-1,697,155
net cash from operating activities																																																																								-4,684,434	-2,460,126	1,296,420	-2,072,384	-2,039,260	3,555,216
capital expenditures																																																																								0	0	0	0	0	0
free cash flows																																																																								-4,684,434	-2,460,126	1,296,420	-2,072,384	-2,039,260	3,555,216
funding of restricted cash
proceeds from sale of intellectual property																																																					1,000,000
purchase of fixed assets
purchase of investment
net cash from investing activities																																																																		-12,309	-741	0	2,873,660	8,578,479	962,828	1,869,918	-82,699	-11,074,771	-49,910	-53,757	-60,988	6,107,779	-5,567,479	2,609,597	1,805,759	1,232,967
net (decrease) in cash and cash equivalents
cash and cash equivalents at beginning of period																																																					34,794,341	0	0	0	57,225,234	0	0	0	38,155,251	0	0	0	29,858,465	0	0	0	11,760,920	0
cash and cash equivalents at end of period																																																					29,388,772	-3,254,754	-4,367,950	-7,056,687	49,473,732	-12,374,965	32,474,193	-14,223,015	51,349,021	2,629,234	-10,856,095	5,219,111	41,163,001	16,689,207	7,183,435	-4,176,523	10,162,346	6,060,222	-4,624,880	-2,780,546	13,106,123	-9,753,615	-1,979,604	16,091,426	11,290,742	7,287,678	232,569	63,416	70,189	56,501
supplemental schedule of cash flow information
noncash financing activities
shares issued for convertible senior notes and accrued interest																																																						0	3,748,518	0	10,132,534
stock warrant expense - noncash																																																										24,221	28,205	102,144	50,410	8,334	0	19,759	37,436		3,209	19,868	11,657	-9,366	50,037	28,649	34,964
loss on disposal or impairment of equipment
investment impairment charge
other non-cash items
changes in assets and liabilities affecting cash flows from operations
purchase of investments
proceeds from sale of fixed assets																																																														825
fractional share payout
cash paid for convertible note repayment
proceeds from common stock option exercises
proceeds from common stock warrant exercises
proceeds from issuance of common stock by underwritten offering
proceeds from issuance of common stock by registered direct offering
net cash from financing activities																																																						-7,933				-1,375,448	45,160,113	-13,281	23,888,627	16,865,766	-264	14,115,849	17,473,307	22,838,146				-60,343	345,750			24,736	142,690	18,184,443	142,662	-1	7,146,937	-6,323	243,675
net increase in cash and cash equivalents																																																																								-2,780,546	-2,542,825	-9,753,615	-1,979,604	16,091,426	3,636,890	7,287,678
interest paid, including acquired accrued interest
noncash investing and financing activities:
investment - non-cash
purchase of fixed assets on account, non-cash investing activity																																																										-37,611	20,630
adjustments to reconcile net loss to net cash from operations
employee & director stock-based compensation																																																							270,002				305,162				268,154	278,665	204,971		305,199	305,199	336,119		305,188	301,111	258,775
prepaid expenses, deposits and other assets																																																							37,308				69,605				-212,610
proceeds from warrants exercised
proceeds from issuance of common stock by underwritten public offering
proceeds from issuance of common stock by registered direct offerings																																																											17,415	-29,672	23,888,627
interest paid																																																							0				0
noncash investing and financing activities
unpaid costs associated with registered direct offering
unpaid costs associated with underwritten public offering
adjustments to reconcile net loss to net cash (used in) operations
net (decrease) cash and cash equivalents
net increase cash and cash equivalents																																																													13,193,770		-10,856,095	5,219,111	11,304,536
excess consideration paid over fair value
loss on disposal of equipment																																																																										0	-2,450
redemption of short term investments																																																																		-11,648	0	0	3,037,982	8,878,288	1,101,354			-1	0			6,094,908	2,324,216	2,683,141	1,902,458	1,350,001
cash paid for transaction related costs
cash received in transaction
liabilities acquired through cell genesys transaction
shares issued for cell genesys transaction
investment aquired through cell genesys transaction
other assets acquired in cell genesys transaction
loss on write-down of fixed assets
investment impairment loss - noncash
proceeds from common stock option exercised
deferred revenue																																																																								-4,545	-4,546	-9,091	-9,091	-6,818	-34,091					-34,091
credit equity financing facility
adjustments to reconcile net loss to net cash used in operating activities:
mark-to-market of convertible senior notes																																																															-103,000	381,916	1,409,000
acquisition related costs
other noncash charges
gain on disposal of fixed assets
changes in other assets and liabilities affecting cash flows from operations:
due to licensor - antares																																																																			-8,329			730	-309	-1,960	5,869
purchase of short term investments																																																																								-15,991	-68,074	-11,053,342	-49,104	-47,545	-60,988
purchase of capital assets																																																																								-114,091	-14,625
cash paid for acquisition related costs
proceeds from sale or conversion of shares																																																															-264	14,115,849	17,473,307	12,134				-60,343	345,750					18,184,443	142,662	-1	7,146,937	-6,323	243,675
supplementary information
other information:
accrued liabilities for acquisition related costs, noncash
adjustments to reconcile net loss to net cash from operating activities:
accrued liabilities for deferred acquisition costs, noncash
adjustments to reconcile net loss to net cash from operating activities
stock warrant expense — noncash
other non-cash charges
fair value adjustment
matc license revenue — noncash
provision for contingencies																																																																													-137,647
due to licensor — antares
purchase of capital assets on account, non-cash investing activity																																																																						-102,421
investment in matc — noncash
impairment of short term investments																																																																							0
(gain) on disposal of equipment
unrealized gain on available-for-sale securities, non-cash
cash flows provided by investing activities
unrealized loss on available-for-sale securities, noncash																																																																									602,000
adjustments to reconcile net income to net cash from operating activities
matc license revenue - noncash
investment in matc - noncash
income tax paid																																																																											0	0	75,000
adjustments to reconcile net loss to
(gain) loss on disposal of equipment
changes in other assets and liabilities
affecting cash flows from operations
cash flows provided by financing activities
at beginning of period																																																																								0	15,648,948		0	0	7,653,852		0	0	310,643
see accompanying notes to the condensed financial statements.
stock warrant expense-noncash
matc license revenue-noncash
due to licensor-antares
supplemental schedule of noncash investing cash flow information
investment in matc
employee & director compensation - noncash																																																																											147,341	142,905	220,798	52,407	49,203	116,209	859,013	87,875
consultant compensation - noncash
prepaid expenses, deposits and other sundry assets																																																																											-200,394				-62,615
accrual for contingencies																																																																											-137,647				-201,765	0	140,000
purchases of capital assets																																																																											-806
proceeds from sale of shares and exercise of options
and warrants
see accompanying notes to the financial statements.
prepaid expenses and other sundry assets																																																																													-8,405				17,500	8,335
amortization of deferred unearned compensation
repurchase of licensing rights
purchased in-process research and development
due from sbi
issuance of convertible debenture
supplemental schedule of
cash flow information
acquisition of sbi
other net liabilities assumed
less: subordinate voting shares issued therefor
-
significant non-cash transactions
fair value of common stock warrants issued in connection
with the sale of capital stock
due from licensee
due to licensor
net cash used in operating activities
net cash provided by financing activities
fair value of common stock warrants issued in connection with the sale of capital stock
accounts payable and accrued expenses
proceeds from sales or conversion of shares
net increase in cash
and cash equivalents
less: common stock issued therefor
cash flows used in operating activities
benefit from contingencies

ANI Pharmaceuticals, Inc(NASDAQ:ANIP)

ANI Pharmaceuticals, Inc
(NASDAQ:ANIP)